

DIGESTIVE DISEASE DAYS

2021

# PROGRAMMA

17 en 18 maart  
DDD Online



DIGESTIVE DISEASE DAYS - DDD

## **Het programma van de DDD Online werd samengesteld met inbreng van de volgende verenigingen en secties:**

Nederlandse Vereniging voor Gastro-enterologie  
Nederlandse Vereniging voor Gastrointestinale Chirurgie  
Nederlandse Vereniging voor Hepatologie  
Nederlandse Vereniging van Maag-Darm-Leverartsen

### **Secties:**

Sectie Gastrointestinale Endoscopie  
Sectie Neurogastroenterologie en Motiliteit  
Sectie Gastrointestinale Oncologie  
Sectie Inflammatoire Darmziekten IBD  
Sectie Kinder-MDL  
Verpleegkundigen & Verzorgenden Nederland – MDL

**Woensdag 17 maart 2021**

Symposium – NVMLD i.o. - Studio 1	5
Symposium – Sectie Gastrointestinale Oncologie - Studio 1	5
Best of Dutch Gastroenterology 2020 - Studio 1	6
Symposium – Nederlandse Vereniging voor Gastrointestinale Chirurgie – Studio 1	6
Symposium – Sectie Inflammatoire Darmziekten - Studio 1	6
President Select - Studio 1	7
Abstractsessie Sectie Inflammatoire Darmziekten - Studio 2	8
Abstractsessie Sectie Neurogastroenterologie en Motiliteit - Studio 2	10
Meet the expert sessie – Thema: Coeliakie - Studio 2	12
Abstractsessie Sectie Gastrointestinale Oncologie - Studio 2	12
Abstractsessie NVGIC - Studio 2	15

**Tijdstippen diverse ledenvergaderingen (ter info: al dan niet separaat van DDD-dagen)**

Nederlandse Vereniging voor Hepatologie*	donderdag 18 maart	18.15 uur
Nederlandse Vereniging van Maag-Darm-Leverartsen*	maandag 22 maart	19.30 uur
Nederlandse Vereniging voor Gastroenterologie*	woensdag 31 maart	19.30 uur

*\*leden ontvangen automatisch een agenda link naar zoom meeting*

**Donderdag 18 maart 2021**

Symposium – Sectie Experimentele Gastroenterologie - Studio 1	17
Symposium Nederlandse Vereniging voor Hepatologie - Studio 1	18
Richtlijn symposium NVMDL - Studio 1	18
Symposium – Sectie Gastrointestinale Endoscopie - Studio 1	19
Symposium – Sectie Kinder-MDL - Studio 1	19
Uitreiking prijzen - Studio 1	20
Abstractsessie Nederlandse Vereniging voor Hepatologie - Studio 2	21
Symposium – Sectie Experimentele Gastroenterologie - Studio 2	23
Meet the expert sessie – Thema: IBS - Studio 2	24
Abstractsessie – Sectie Inflammatoire Darmziekten - Studio 2	24
Abstractsessie – Sectie Gastrointestinale Endoscopie - Studio 2	27
Symposium – V&VN MDL – Endoscopie - Studio 2	30
Symposium – V&VN MDL – IBD - Studio 2	30
Abstractsessie – V&VN MDL - Studio 2	31

---

**Symposium – NVMLD i.o.**

**Studio I**

Voorzitters: *W.P. Brouwer en D.S.J. Wintjens*

**The future is now**

- 08.30      Gebruik van big data en machine learning in de dagelijks praktijk  
*Dr. M. de Nerée tot Babberich, product Owner, Pacmed, Amsterdam*
- 08.50      Virtual reality en artificial intelligence binnen de endoscopie  
*Prof. dr. E.J. Schoon, MDL-arts, Catharina Ziekenhuis, Eindhoven*
- 09.10      Duurzaamheid bij de MDL, wat is onze rol?  
*Dr. M. Duijvestein, MDL-arts, Amsterdam UMC, loc. VUmc*
- 09.30      Einde van dit programma onderdeel

---

**Symposium – Sectie Gastrointestinale Oncologie**

**Studio I**

Voorzitters: *L. Brouwer-Hol en E.A.R. Gielisse*

**Voeding bij kanker**

- 10.00      Voeding en kanker  
*Dr. F.J.B. van Duijnhoven, Universitair Docent Voeding, genen en dikkedarmkanker, WUR*
- 10.15      Voeding bij pancreascarcinoom  
*Dr. M. van Driel, Radboudumc, Nijmegen*
- 10.30      Endoscopische gastrojejunostomie  
*Prof. dr. F.P. Vleggaar, MDL-arts, UMCU, Utrecht*
- 10.45      Discussie  
*Alle sprekers*
- 11.00      Einde van dit programma onderdeel

---

**Best of Dutch Gastroenterology 2020**

---

**Studio I**

Voorzitters: *L.P.S. Stassen en W.H. de Vos tot Nederveen Cappel*

**State of the art lectures**

- 11.30 A celiac mucosal barrier on-chip model to investigate its role in initiation of celiac disease  
*Dr. S. Withoff, associate professor, Universitair Medisch Centrum Groningen*
- 11.50 Best of Dutch Endoscopy 2020  
*Prof. E.J. Schoon, MDL-arts, Catharina Ziekenhuis, Eindhoven*
- 12.10 Best of Dutch Gastric Cancer 2020  
*Dr. J.W. van Sandick, chirurg, NKI Antoni van Leeuwenhoek, Amsterdam*
- 12.30 Einde van dit programma onderdeel

---

**Symposium – Nederlandse Vereniging voor Gastrointestinale Chirurgie**

---

**Studio I**

Voorzitters: volgt.

- 14.00 Kock's Pouch  
*Dr. M. Gerhards, chirurg, OLVG, Amsterdam*
- 14.20 Rol van mesenterium in IBD  
*Dr. C.J. Buskens, chirurg, Amsterdam UMC, loc. AMC*
- 14.40 Sonde-voeding als work-up voor ileocoecalresectie  
*Dr. A.C. de Vries, MDL-arts, Erasmus MC, Rotterdam*
- 15.00 Afsluiting programma onderdeel

---

**Symposium – Sectie Inflammatoire Darmziekten**

---

**Studio I**

Voorzitters: *J.J.L. Haans en S. Popal*

**IBD@Home**

- 15.30 Thuistherapie en thuismonitoring  
*Dr. M.C. Visschedijk, MDL-arts, Universitair Medisch Centrum Groningen*
- 15.45 eHealth in de IBD praktijk  
*Dr. M.J.L. Romberg-Camps, MDL-arts, Zuyderland, Sittard-Geleen*
- 16.00 Waardegedreven zorg  
*P. de Bey, Directeur Santeon, Utrecht*
- 16.15 Discussie met alle sprekers tot 16.30 uur.

Voorzitters: C.J. van der Woude en A.E. van der Meulen

- 17.00 Insufficient evidence that polygenetic risk scores can be used to predict response to anti-TNF $\alpha$  therapy in inflammatory bowel disease  
N. Karmi<sup>1</sup>, A. Bangma<sup>1</sup>, L.M. Spekhorst<sup>1</sup>, H.M. Van Dullemen<sup>1</sup>, M.C. Visschedijk<sup>1</sup>, G. Dijkstra<sup>1</sup>, R.K. Weersma<sup>1</sup>, M.D. Voskuil<sup>1</sup>, E.A.M. Festen<sup>1</sup> <sup>1</sup>Dept. of Gastroenterology and Hepatology, UMCG, Groningen, The Netherlands.
- 17.10 Dietary inflammatory index and diet quality in inflammatory bowel disease and irritable bowel syndrome patients  
M.C.G. de Graaf<sup>1</sup>, C.E.G.M. Spooren<sup>1</sup>, E.J. den Brok<sup>1</sup>, E.J.M. Feskens<sup>2</sup>, D. Keszthelyi<sup>1</sup>, M.J. Pierik<sup>1</sup>, D.M.A.E. Jonkers<sup>1</sup> <sup>1</sup>Dept. of Gastroenterology and Hepatology, Maastricht University Medical Center, Maastricht, The Netherlands, <sup>2</sup>Dept. of Human Nutrition and Health, Wageningen University & Research, Wageningen, The Netherlands.
- 17.20 A randomized trial of aggressive fluid hydration to prevent post-ERCP pancreatitis (FLUYT)  
C.J. Sperna Weiland<sup>1</sup>, X.J.N.M. Smeets<sup>1</sup>, W. Kievit<sup>1</sup>, R.C. Verdonk<sup>2</sup>, A.C. Poen<sup>3</sup>, A. Bhalla<sup>4</sup>, N.G. Venneman<sup>5</sup>, B.J.M. Witteman<sup>6</sup>, D.W. Da Costa<sup>7</sup>, B.C. Van Eijck<sup>8</sup>, M.P. Schwartz<sup>9</sup>, T.E.H. Römken<sup>10</sup>, J.M. Vrolijk<sup>11</sup>, M. Hadithi<sup>12</sup>, A.M.C.J. Voorburg<sup>13</sup>, L.C. Baak<sup>14</sup>, W.J. Thijs<sup>15</sup>, R.L. Van Wanrooij<sup>16</sup>, A.C.I.T.L. Tan<sup>17</sup>, T.C.J. Seerden<sup>18</sup>, Y.C.A. Keulemans<sup>19</sup>, T.R. De Wijkerslooth<sup>20</sup>, W. Van de Vrie<sup>21</sup>, P. Van der Schaar<sup>2</sup>, S.M. Van Dijk<sup>22</sup>, N.D.L. Hallensleben<sup>23</sup>, R.L. Sperna Weiland<sup>24</sup>, H.C. Timmerhuis<sup>2</sup>, D.S. Umans<sup>2</sup>, J.E. Van Hooft<sup>25</sup>, H. Van Goor<sup>26</sup>, H.C. Van Santvoort<sup>27</sup>, M.G. Besselink<sup>22</sup>, M.J. Bruno<sup>28</sup>, P. Fockens<sup>16</sup>, J.P.H. Drenth<sup>1</sup>, E.J.M. Van Geenen<sup>1</sup> <sup>1</sup>Dept. of Gastroenterology and Hepatology, Radboudumc, Nijmegen, Nederland, <sup>2</sup>Dept. of Gastroenterology and Hepatology, St. Antonius ziekenhuis, Nieuwegein, Nederland, <sup>3</sup>Dept. of Gastroenterology and Hepatology, Isala ziekenhuis, Zwolle, Nederland, <sup>4</sup>Dept. of Gastroenterology and Hepatology, Haga ziekenhuis, Den Haag, Nederland, <sup>5</sup>Dept. of Gastroenterology and Hepatology, Medisch Spectrum Twente, Enschede, Nederland, <sup>6</sup>Dept. of Gastroenterology and Hepatology, Ziekenhuis Gelderse Vallei, Ede, Nederland, <sup>7</sup>Dept. of Radiology, St. Antonius ziekenhuis, Nieuwegein, Nederland, <sup>8</sup>Dept. of Gastroenterology and Hepatology, Spaarne gasthuis, Hoofddorp, Nederland, <sup>9</sup>Dept. of Gastroenterology and Hepatology, Meander MC, Amersfoort, Nederland, <sup>10</sup>Dept. of Gastroenterology and Hepatology, Jeroen Bosch ziekenhuis, Den Bosch, Nederland, <sup>11</sup>Dept. of Gastroenterology and Hepatology, Rijnstate ziekenhuis, Arnhem, Nederland, <sup>12</sup>Dept. of Gastroenterology and Hepatology, Maastad ziekenhuis, Rotterdam, Nederland, <sup>13</sup>Dept. of Gastroenterology and Hepatology, Diaconessenhuis, Utrecht, Nederland, <sup>14</sup>Dept. of Gastroenterology and Hepatology, OLVG, Amsterdam, Nederland, <sup>15</sup>Dept. of Gastroenterology and Hepatology, Martini ziekenhuis, Groningen, Nederland, <sup>16</sup>Dept. of Gastroenterology and Hepatology, Amsterdam UMC, Amsterdam, Nederland, <sup>17</sup>Dept. of Gastroenterology and Hepatology, Canisius Wilhelmina ziekenhuis, Nijmegen, Nederland, <sup>18</sup>Dept. of Gastroenterology and Hepatology, Amphia ziekenhuis, Breda, Nederland, <sup>19</sup>Dept. of Gastroenterology and Hepatology, Zuyderland ziekenhuis, Heerlen, Nederland, <sup>20</sup>Dept. of Gastroenterology and Hepatology, Antoni van Leeuwenhoekziekenhuis, Amsterdam, Nederland, <sup>21</sup>Dept. of Gastroenterology and Hepatology, Albert Schweitzer ziekenhuis, Dordrecht, Nederland, <sup>22</sup>Dept. of Surgery, Amsterdam UMC, Amsterdam, Nederland, <sup>23</sup>Dept. of Anesthesiology, Erasmus MC, Rotterdam, Nederland, <sup>24</sup>Dept. of Gastroenterology and Hepatology, University of Amsterdam, Amsterdam, Nederland, <sup>25</sup>Dept. of Gastroenterology and Hepatology, Leids Universitair Medisch Centrum, Leiden, Nederland, <sup>26</sup>Dept. of Surgery, Radboudumc, Nijmegen, Nederland, <sup>27</sup>Dept. of Surgery, St. Antonius ziekenhuis, Nieuwegein, Nederland, <sup>28</sup>Dept. of Gastroenterology and Hepatology, Erasmus MC, Rotterdam, Nederland.

**Invited speakers**

- 17.30 Checkpoint inhibitor-induced colitis: prevalentie, diagnostiek en behandeling  
*Dr. J.M. van Dieren, MDL-arts, NKI Antoni van Leeuwenhoek, Amsterdam, en  
Dr. K.P.M. Suijkerbuijk, internist-oncoloog, UMC Utrecht*
- 18.00 Afsluiting programma onderdeel

---

**Abstractsessie Sectie Inflammatoire Darmziekten**

**Studio 2**

---

Voorzitters: *M. Lutgens en F. Van Schaik*

- 08.30 Locally injected allogeneic bone marrow-derived mesenchymal stromal cells for the treatment of refractory proctitis: clinical results of a phase IIa trial.  
*L.F. Ouboter<sup>1</sup>, M.C. Barnhoorn<sup>1</sup>, L.J.A.C. Hawinkels<sup>1</sup>, M. van Pel<sup>2</sup>, J.J. de Zwaginga<sup>3</sup>, F. de Koning<sup>4</sup>, H.W. Verspaget<sup>1</sup>, A.E. van der Meulen - de Jong<sup>1</sup>* <sup>1</sup>Dept. of Gastroenterology and Hepatology, Leids Universitair Medisch Centrum, Leiden, Nederland, <sup>2</sup>Dept. of Immunohematology and Blood Transfusion, Netherlands Center for the Clinical Advancement of Stem Cell & Gene Therapies, Leiden, The Netherlands, <sup>3</sup>Dept. of Immunology, Leids Universitair Medisch Centrum, Leiden, Nederland, <sup>4</sup>Dept. of Immunopathology, Leids Universitair Medisch Centrum, Leiden, Nederland.
- 08.36 Histopathological features at Crohn's disease diagnosis as predictors for long-term disease course: results from the population-based IBD South-Limburg cohort  
*A. Rezazadeh Ardabili<sup>1</sup>, D. Goudkade<sup>2</sup>, D.S.J. Wintjens<sup>1</sup>, M.J.L. Romberg-Camps<sup>3</sup>, B. Winkens<sup>4</sup>, H.I. Grabsch<sup>5</sup>, M.J. Pierik<sup>1</sup>, D.M.A.E. Jonkers<sup>1</sup>* <sup>1</sup>Dept. of Gastroenterology and Hepatology, Maastricht University Medical Center+, Maastricht, The Netherlands, <sup>2</sup>Dept. of Pathology, Zuyderland Medical Center, Sittard-Geleen, The Netherlands, <sup>3</sup>Dept. of Gastroenterology and Hepatology, Zuyderland Medical Center, Sittard-Geleen, The Netherlands, <sup>4</sup>Dept. of Epidemiology, Maastricht University, Maastricht, The Netherlands, <sup>5</sup>Dept. of Pathology, Maastricht University Medical Center+, Maastricht, The Netherlands.
- 08.42 Healthy cotwins share gut microbiome signatures with their inflammatory bowel disease twins and unrelated patients  
*M.A.Y. Klaassen<sup>1</sup>, E.C. Brand<sup>2</sup>, R. Gacesa<sup>1</sup>, A. Vich Vila<sup>1</sup>, H. Ghosh<sup>1</sup>, M.R. de Zoete<sup>3</sup>, D.I. Boomsma<sup>4</sup>, F. Hoentjen<sup>5</sup>, C.S. Horjus Talabur Horje<sup>6</sup>, P.C. van de Meeberg<sup>7</sup>, A.H.M. Willemsen<sup>4</sup>, J. Fu<sup>8</sup>, C. Wijmenga<sup>9</sup>, F. van Wijk<sup>10</sup>, A. Zhernakova<sup>9</sup>, B. Oldenburg<sup>2</sup>, R.K. Weersma<sup>1</sup>* <sup>1</sup>Dept. of Gastroenterology and Hepatology, University Medical Center Groningen, Groningen, Nederland, <sup>2</sup>Dept. of Gastroenterology and Hepatology, University Medical Center Utrecht, Utrecht, Nederland, <sup>3</sup>Dept. of Medical Microbiology, University Medical Center Utrecht, Utrecht, Nederland, <sup>4</sup>Dept. of Scientific Research, Vrije Universiteit Medical Center, Amsterdam, Nederland, <sup>5</sup>Dept. of Gastroenterology and Hepatology, Radboud University Medical Center, Nijmegen, Nederland, <sup>6</sup>Dept. of Gastroenterology and Hepatology, Rijnstate Hospital, Arnhem, Nederland, <sup>7</sup>Dept. of Gastroenterology and Hepatology, Slingeland Hospital, Doetinchem, Nederland, <sup>8</sup>Dept. of Pediatric Gastroenterology Hepatology and Nutrition, University Medical Center Groningen, Groningen, Nederland, <sup>9</sup>Dept. of Clinical Genetics, University Medical Center Groningen, Groningen, Nederland, <sup>10</sup>Centre for Translational Immunology, University Medical Center Utrecht, Utrecht, Nederland.



Woensdag 17 maart 2021

- 08.48 Western and carnivorous dietary patterns are associated with greater likelihood of IBD occurrence in a large prospective population-based cohort  
V. Peters<sup>1</sup>, L.A. Bolte<sup>1</sup>, E.M. Schuttert<sup>1</sup>, S. Andreu-Sánchez<sup>1</sup>, G. Dijkstra<sup>1</sup>, R.K. Weersma<sup>1</sup>, M.J.E. Campmans-Kuijpers<sup>1</sup> <sup>1</sup>Dept. of Gastroenterology and Hepatology, UMCG, Groningen, The Netherlands.
- 08.54 Host-genetics, dysbiosis, and clinical history explains fecal metabolic alterations in patients with inflammatory bowel disease  
A. Vich Vila<sup>1</sup>, S. Hu<sup>1</sup>, S. Andreu-Sánchez<sup>2</sup>, L. Bolte<sup>1</sup>, V. Collij<sup>1</sup>, B.H. Jansen<sup>1</sup>, R.A.A.A. Ruigrok<sup>1</sup>, G. Abu-Ali<sup>3</sup>, C. Giallourakis<sup>3</sup>, J. Schneider<sup>3</sup>, J. Parkinson<sup>3</sup>, A. Al Garawi<sup>3</sup>, A. Kurilshikov<sup>2</sup>, R. Gacesa<sup>1</sup>, A. Zhernakova<sup>2</sup>, J. Fu<sup>2</sup>, R.K. Weersma<sup>1</sup> <sup>1</sup>Dept. of Gastroenterology and Hepatology, Universitair Medisch Centrum Groningen, Groningen, Nederland, <sup>2</sup>Dept. of Clinical Genetics, Universitair Medisch Centrum Groningen, Groningen, Nederland, <sup>3</sup>Dept. of Gastroenterology, Takeda Pharmaceutical Company Limited, Cambridge, Verenigde Staten.
- 09.00 The effect of phenotype and genotype on the plasma proteome in patients with inflammatory bowel disease  
A.R. Bourgonje<sup>1</sup>, S. Hu<sup>1</sup>, L.M. Spekhorst<sup>1</sup>, D.V. Zhernakova<sup>2</sup>, A. Vich Vila<sup>1</sup>, Y. Li<sup>1</sup>, M.D. Voskuil<sup>1</sup>, L.A. van Berke<sup>3</sup>, B. Bley Folly<sup>3</sup>, M. Charrout<sup>4</sup>, A. Mahfouz<sup>4</sup>, M.J.T. Reinders<sup>4</sup>, M.C. Visschedijk<sup>1</sup>, H.M. van Dullemen<sup>1</sup>, K.N. Faber<sup>1</sup>, J.N. Samsom<sup>3</sup>, E.A.M. Festen<sup>1</sup>, G. Dijkstra<sup>1</sup>, R.K. Weersma<sup>1</sup> <sup>1</sup>Dept. of Gastroenterology and Hepatology, University of Groningen, University Medical Center Groningen, Groningen, <sup>2</sup>Dept. of Clinical Genetics, University of Groningen, University Medical Center Groningen, Groningen, <sup>3</sup>Dept. of Pediatric Gastroenterology Hepatology and Nutrition, Erasmus University Medical Center, Rotterdam, Nederland, <sup>4</sup>Delft Bioinformatics Lab, Delft University of Technology, Delft, Nederland.
- 09.06 Inflammation status modulates the effect of host genetic variation on intestinal gene expression in inflammatory bowel disease  
S.H. Hu<sup>2</sup>, WUV T. Uniken Venema<sup>2</sup>, H.W. Westra<sup>3</sup>, A.V. Vich Vila<sup>2</sup>, R.B. Barbieri<sup>2</sup>, M.V.D. Voskuil<sup>2</sup>, T.B. Blokzijl<sup>2</sup>, B.J. Jansen<sup>2</sup>, L.Y. Yanni<sup>2</sup>, M.D. Daly<sup>4</sup>, R.X. Xavier<sup>5</sup>, G.D. Dijkstra<sup>2</sup>, E.F. Festen<sup>2</sup>, R.K. Weersma<sup>2</sup>, <sup>1</sup>Dept. of Gastroenterology and Hepatology, University of Groningen and University Medical Center Groningen, Department of G, Groningen, Nederland, <sup>2</sup>Dept. of Gastroenterology and Hepatology, University of Groningen and University Medical Center Groningen, Groningen, Nederland, <sup>3</sup>Dept. of Clinical Genetics, University of Groningen and University Medical Center Groningen, Groningen, Nederland, <sup>4</sup>Dept. of Medicine, University of Helsinki, Helsinki, Finland, <sup>5</sup>Dept. of Microbiology and Systems Biology, Massachusetts Institute of Technology, Cambridge, Verenigde Staten.
- 09.12 Point-of-Care Intestinal Ultrasound provides additional information about disease activity in pediatric Crohn's Disease patients visiting the outpatient department  
E.A. van Wassenae<sup>1</sup>, J.E. van Limbergen<sup>1</sup>, G.R. D'Haens<sup>2</sup>, M.A. Benninga<sup>1</sup>, B.G.P. Koot<sup>1</sup> <sup>1</sup>Dept. of Pediatric Gastroenterology Hepatology and Nutrition, Emma Kinderziekenhuis, Amsterdam UMC, Universiteit van Amsterdam, Amsterdam,, <sup>2</sup>Dept. of Gastroenterology and Hepatology, Amsterdam UMC, Universiteit van Amsterdam, Amsterdam.
- 09.18 Decrease in bowel wall thickness at intestinal ultrasound accurately detects early endoscopic remission and treatment response in ulcerative colitis patients on tofacitinib: a longitudinal prospective cohort study  
F.A.E. De Voogd<sup>1</sup>, E.A. Van Wassenae<sup>2</sup>, A. Mookhoek<sup>3</sup>, S. Bots<sup>1</sup>, S. Van Gennep<sup>1</sup>, M. Duijvestein<sup>1</sup>, C. Ponsioen<sup>1</sup>, M. Löwenberg<sup>1</sup>, G. D'Haens<sup>1</sup>, K. Gecse<sup>1</sup> <sup>1</sup>Dept. of Gastroenterology and Hepatology, Amsterdam UMC, Amsterdam,, <sup>2</sup>Dept. of Pediatrics, Amsterdam UMC, Amsterdam, Nederland, <sup>3</sup>Dept. of Pathology, Amsterdam UMC, Amsterdam, Nederland.
- 09.30 Einde van dit programma onderdeel

Voorzitters: F. van Hoeij en D. Keszthelyi

- 10.00 Appropriateness of Proton Pump Inhibitor Prescriptions in Clinical Practice  
L.M. de Koggel<sup>1</sup>, M.A. Lantinga<sup>1</sup>, F.L. Büchner<sup>2</sup>, M.E. Numans<sup>2</sup>, M. Heringa<sup>3</sup>, J.P.H. Drenth<sup>1</sup>, P.D. Siersema<sup>1</sup>, <sup>1</sup>Dept. of Gastroenterology and Hepatology, Radboudumc, Nijmegen, <sup>2</sup>Dept. of Public Health, Leids Universitair Medisch Centrum, Leiden, <sup>3</sup>Dept. of Clinical Pharmacy, SIR Institute for Pharmacy Practice and Policy, Leiden, The Netherlands.
- 10.06 A trial-based economic evaluation of peppermint oil for the treatment of Irritable Bowel Syndrome  
Z.Z.R.M. Weerts<sup>1</sup>, B.A.B. Essers<sup>2</sup>, DMAE Jonkers<sup>1</sup>, J.I.A. Willems<sup>1</sup>, D.P.J.P.A. Janssen<sup>1</sup>, B.J.M. Witteman<sup>3</sup>, C.H.M. Clemens<sup>4</sup>, A. Westendorp<sup>5</sup>, A.A.M. Masclee<sup>1</sup>, D. Keszthelyi<sup>1</sup>, <sup>1</sup>Dept. of Gastroenterology and Hepatology, Maastrichtuniversity.nl, Maastricht, Nederland, <sup>2</sup>Dept. of Clinical Epidemiology and Medical Technology Assessment, Maastricht University, Maastricht, Nederland, <sup>3</sup>Dept. of Gastroenterology and Hepatology, Ziekenhuis Gelderse Vallei, Ede, Nederland, <sup>4</sup>Dept. of Gastroenterology, Alrijne Ziekenhuis, Leiden, Nederland, <sup>5</sup>Dept. of Gastroenterology and Hepatology, Leeuwarden Medisch Centrum, Leeuwarden, Nederland.
- 10.12 Factors affecting the placebo response rate in pharmacological trials in patients with irritable bowel syndrome – a systematic review and meta-analysis  
M. Bosman<sup>1</sup>, S. Elsenbruch<sup>2</sup>, M. Corsetti<sup>3</sup>, J. Tack<sup>4</sup>, M. Simrén<sup>5</sup>, B. Winkens<sup>6</sup>, T. Boumans<sup>1</sup>, A. Masclee<sup>1</sup>, D. Keszthelyi<sup>1</sup> <sup>1</sup>Dept. of Gastroenterology and Hepatology, Maastricht UMC+, Maastricht, Nederland, <sup>2</sup>Dept. of Physiology, Ruhr University Bochum, Bochum, Duitsland, <sup>3</sup>Dept. of Research & Development, Nottingham University Hospitals NHS Trust, Nottingham, Verenigd Koninkrijk, <sup>4</sup>Dept. of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, België, <sup>5</sup>Dept. of Medicine, University of Gothenburg, Gothenburg, Zweden, <sup>6</sup>Dept. of Research & Development, Maastricht University, Maastricht, Nederland.
- 10.18 Do patients' and physicians' perspectives differ on preferences for IBS treatment? - a qualitative study to explore attributes for quantitative preference elicitation  
R. Sturkenboom<sup>1</sup>, B.A.B. Essers<sup>2</sup>, A.A.M. Masclee<sup>1</sup>, D. Keszthelyi<sup>1</sup> <sup>1</sup>Dept. of Gastroenterology and Hepatology, MUMC+, Maastricht, Nederland, <sup>2</sup>Dept. of Clinical Epidemiology and Medical Technology Assessment (KEMTA), MUMC+, Maastricht, Nederland.
- 10.24 Examining the optimal cut-off values of HADS, PHQ-9 and GAD-7 as screening instruments for depression and anxiety in Irritable Bowel Syndrome  
J.T.W. Snijkers<sup>1</sup>, W. van den Oever<sup>1</sup>, Z.Z.R.M. Weerts<sup>1</sup>, L. Vork<sup>1</sup>, Z. Mujagic<sup>1</sup>, C. Leue<sup>2</sup>, M.A.M. Hesselink<sup>3</sup>, J.W. Kruijmel<sup>1</sup>, J.W.M. Muris<sup>4</sup>, R.M.M. Bogie<sup>1</sup>, A.A.M. Masclee<sup>1</sup>, D.M.A.E. Jonkers<sup>3</sup>, D. Keszthelyi<sup>1</sup> <sup>1</sup>Dept. of Gastroenterology and Hepatology, MUMC+ / Maastricht University, Maastricht, The Netherlands, <sup>2</sup>Dept. of Psychiatry, MUMC+ / Maastricht University, Maastricht, The Netherlands, <sup>3</sup>Dept. of Gastroenterology and Hepatology, Maastricht University, Maastricht, The Netherlands, <sup>4</sup>Dept. of Public Health, Maastricht University, Maastricht, The Netherlands.
- 10.30 The interplay between stress and fullness in functional dyspepsia and healthy controls: an exploratory experience sampling method study  
T. Klaassen<sup>1</sup>, L. Vork<sup>1</sup>, F.G.M. Smeets<sup>1</sup>, F.J. Troost<sup>1</sup>, J.W. Kruijmel<sup>1</sup>, C. Leue<sup>2</sup>, A.A.M. Masclee<sup>1</sup>, D. Keszthelyi<sup>1</sup> <sup>1</sup>Dept. of Gastroenterology and Hepatology, Maastricht University Medical Center+, Maastricht, The Netherlands, <sup>2</sup>Dept. of Psychiatry, Maastricht University Medical Center+, Maastricht, The Netherlands.

- 10.36 The Dutch Microbiome Project defines factors that shape the healthy gut microbiome  
*R. Gacesa<sup>1</sup>, A. Kurilshikov<sup>2</sup>, A. Vich Vila<sup>3</sup>, T. Sinha<sup>2</sup>, M.A.Y. Klaasen<sup>3</sup>, L.A. Bolte<sup>3</sup>, S. Andreu-Sanchez<sup>2</sup>, L. Chen<sup>2</sup>, V. Collij<sup>3</sup>, S. Hu<sup>3</sup>, J.A.M. Dekens<sup>2</sup>, V.C. Lenters<sup>4</sup>, J. R. Bjork<sup>3</sup>, J.C. Swarte<sup>3</sup>, M. A. Swertz<sup>2</sup>, B.H. Jansen<sup>3</sup>, J. Gelderloos-Arends<sup>2</sup>, M. Hofker<sup>2</sup>, R.C.H. Vermeulen<sup>4</sup>, S. Sanna<sup>5</sup>, H. J. M. Harmsen<sup>6</sup>, C. Wijmenga<sup>2</sup>, J. Fu<sup>7</sup>, A. Zhernakova<sup>2</sup>, R.K. Weersma<sup>3</sup> <sup>1</sup>Dept. of Gastroenterology and Hepatology, University Medical Center Groningen (UMCG), Groningen, The Netherlands, <sup>2</sup>Dept. of Clinical Genetics, University of Groningen and University Medical Center Groningen, Groningen, Nederland, <sup>3</sup>Dept. of Gastroenterology and Hepatology, University of Groningen and University Medical Center Groningen, Groningen, Nederland, <sup>4</sup>Dept. Julius Center for Health Sciences and Primary Care, University Medical Centre Utrecht, Utrecht, The Netherlands, <sup>5</sup>Dept. of Scientific Research, Institute for Genetic and Biomedical Research, Cagliari, Italië, <sup>6</sup>Dept. of Medical Microbiology, University of Groningen and University Medical Center Groningen, Groningen, Nederland, <sup>7</sup>Dept. of Pediatrics, University of Groningen and University Medical Center Groningen, Groningen, Nederland.*
- 10.42 Growth and fat mass, but not fat-free mass, are compromised in infants with parenteral nutrition need after neonatal intestinal surgery  
*LE Vlug<sup>1</sup>, EG Neelis<sup>1</sup>, WLM Kastelij<sup>2</sup>, JF Olieman<sup>2</sup>, MJ Vermeulen<sup>3</sup>, JA Roelants<sup>3</sup>, D Rizopoulos<sup>4</sup>, JCK Wells<sup>5</sup>, MS Fewtrell<sup>6</sup>, RMH Wijnen<sup>7</sup>, EHHM Rings<sup>1</sup>, BAE de Koning<sup>1</sup>, JM Hulst<sup>8</sup> <sup>1</sup>Dept. of Pediatric Gastroenterology Hepatology and Nutrition, Erasmus MC University Medical Center-Sophia Children's Hospital, Rotterdam, The Netherlands, <sup>2</sup>Dept. of Dietetics, Erasmus MC University Medical Center-Sophia Children's Hospital, Rotterdam, The Netherlands, <sup>3</sup>Dept. of Pediatrics, Erasmus MC University Medical Center-Sophia Children's Hospital, Rotterdam, The Netherlands, <sup>4</sup>Dept. of Biostatistics, Erasmus MC University Medical Center, Rotterdam, The Netherlands, <sup>5</sup>Dept. of Human Nutrition and Health, UCL Great Ormond Street Institute of Child Health, London, Verenigd Koninkrijk, <sup>6</sup>Dept. of Public Health, UCL Great Ormond Street Institute of Child Health, London, Verenigd Koninkrijk, <sup>7</sup>Dept. of Surgery, Erasmus MC University Medical Center-Sophia Children's Hospital, Rotterdam, The Netherlands, <sup>8</sup>Dept. of Pediatric Gastroenterology Hepatology and Nutrition, The Hospital for Sick Children, Toronto, Canada.*
- 10.48 Health-Related Quality of Life of Children on Home Parenteral Nutrition  
*SCJ Nagelkerke<sup>1</sup>, HA van Oers<sup>2</sup>, L Haverman<sup>2</sup>, BAE de Koning<sup>3</sup>, MA Benninga<sup>1</sup>, MM Tabbers<sup>1</sup> <sup>1</sup>Dept. of Pediatric Gastroenterology Hepatology and Nutrition, Emma Children's Hospital, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands, <sup>2</sup>Dept. of Pediatric Medical Psychology and Social Work, Emma Children's Hospital, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands, <sup>3</sup>Dept. of Pediatric Gastroenterology Hepatology and Nutrition, Sophia Children's Hospital, Erasmus University Medical Center, Rotterdam, The Netherlands.*
- 11.00 Einde van dit programma onderdeel

11.30 uur – 12.30 uur

**Thema: Coeliakie**

Deze sessies – waarvoor tevoren moet worden ingeschreven - worden verzorgd door:  
Prof. dr. L. Mearin, kinderarts-MDL, LUMC, Leiden  
Dr. P.J. Wahab, MDL-arts, Rijnstate ziekenhuis, Arnhem

12.30 Einde van dit programma onderdeel, mogelijkheid tot volgen netwerksessie tot 14.00

Voorzitters: C. le Clercq en L.G. van Vlerken

- 14.00 Screening for synchronous esophageal second primary tumors in patients with head and neck cancer  
S.E.M. van de Ven<sup>1</sup>, W. de Graaf<sup>1</sup>, O. Bugter<sup>2</sup>, M.C.W. Spaander<sup>1</sup>, S. Nikkessen<sup>1</sup>, P.J.F. de Jonge<sup>1</sup>, J.A. Hardillo<sup>2</sup>, A. Sewnaik<sup>2</sup>, D.A. Monserez<sup>2</sup>, H. Mast<sup>2</sup>, S. Keereweer<sup>2</sup>, M.J. Bruno<sup>1</sup>, R.J. Baatenburg de Jong<sup>2</sup>, A.D. Koch<sup>1</sup> <sup>1</sup>Dept. of Gastroenterology and Hepatology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, The Netherlands, <sup>2</sup>Dept. of Otorhinolaryngology and Head and Neck Surgery, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, The Netherlands.
- 14.06 Neoplastic recurrence after successful treatment for early Barrett's neoplasia: development of a penalized prediction model.  
S.N. van Munster<sup>1</sup>, E.A. de Nieuwenhuis<sup>1</sup>, B.L.A.M. Weusten<sup>2</sup>, L. Alvarez Herrero<sup>2</sup>, A. Bogte<sup>3</sup>, A. Alkhalaf<sup>4</sup>, B.E. Schenk<sup>4</sup>, E. Schoon<sup>5</sup>, W.L. Curvers<sup>5</sup>, A.D. Koch<sup>6</sup>, P.J. de Jonge<sup>6</sup>, T. Tang<sup>7</sup>, W.B. Nagengast<sup>8</sup>, J. Westerhof<sup>8</sup>, M.H.M.G. Houben<sup>9</sup>, J.J.G.H.M. Bergman<sup>1</sup>, R.E. Pouw<sup>1</sup> <sup>1</sup>Dept. of Gastroenterology and Hepatology, Amsterdam UMC, location VUmc, Amsterdam,, <sup>2</sup>Dept. of Gastroenterology and Hepatology, Sint Antonius Hospital Nieuwegein, Nieuwegein,, <sup>3</sup>Dept. of Gastroenterology and Hepatology, University Medical Center Utrecht, Utrecht,, <sup>4</sup>Dept. of Gastroenterology and Hepatology, Isala Clinics, Zwolle, <sup>5</sup>Dept. of Gastroenterology and Hepatology, Catharina Hospital, Eindhoven, <sup>6</sup>Dept. of Gastroenterology and Hepatology, Erasmus Medical Center, Rotterdam,, <sup>7</sup>Dept. of Gastroenterology and Hepatology, IJsselland Hospital, Capelle a/d IJssel, The Netherlands, <sup>8</sup>Dept. of Gastroenterology and Hepatology, University Medical Center Groningen, Groningen, The Netherlands, <sup>9</sup>Dept. of Gastroenterology and Hepatology, Haga Teaching Hospital, Den Haag, The Netherlands.
- 14.12 Circulating TP53 mutations are predictive and prognostic biomarkers in pancreatic cancer patients treated with FOLFIRINOX chemotherapy  
F Van der Sijde<sup>1</sup>, Z Azmani<sup>2</sup>, M.G. Besselink<sup>3</sup>, BA Bonsing<sup>4</sup>, J.W.B. De Groot<sup>5</sup>, Groot Koerkamp<sup>1</sup>, B.C.M. Haberkorn<sup>6</sup>, M.Y.V.Homs<sup>7</sup>, W.F.J. Van Ijcken<sup>2</sup>, QP Janssen<sup>1</sup>, L.J.M. Mekenkamp<sup>8</sup>, SAC Luelmo<sup>9</sup>, DAM Mustafa<sup>10</sup>, RHN Van Schaik<sup>11</sup>, JW Wilmink<sup>12</sup>, CHJ Van Eijck<sup>1</sup>, EE Vietsch<sup>1</sup>, <sup>1</sup>Dept. of Surgery, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands, <sup>2</sup>Dept. of Cell and Chemical Biology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands, <sup>3</sup>Dept. of Surgery, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands, <sup>4</sup>Dept. of Surgery, Leiden University Medical Center, Leiden, The Netherlands, <sup>5</sup>Dept. of Medical Oncology, Isala Hospital, Zwolle, The Netherlands, <sup>6</sup>Dept. of Medical Oncology,

Maasstad Hospital, Rotterdam, The Netherlands, <sup>7</sup>Dept. of Medical Oncology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands, <sup>8</sup>Dept. of Medical Oncology, Medisch Spectrum Twente, Enschede, The Netherlands, <sup>9</sup>Dept. of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands, <sup>10</sup>Dept. of Pathology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands, <sup>11</sup>Dept. of Clinical Laboratory, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands, <sup>12</sup>Dept. of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.

- 14.18 Dietary intake influences the response to cancer immunotherapy  
L.A. Bolte<sup>1</sup>, K.A. Lee<sup>2</sup>, J. Björk<sup>1</sup>, A.M. Thomas<sup>3</sup>, E. Leeming<sup>4</sup>, L. Kist de Ruijter<sup>5</sup>, V. Bataille<sup>4</sup>, N. Segata<sup>3</sup>, T. Spector<sup>4</sup>, R.S.N. Fehrmann<sup>6</sup>, G.A.P. Hospers<sup>6</sup>, R.K. Weersma<sup>1</sup>, <sup>1</sup>Dept. of Gastroenterology and Hepatology, University Medical Center Groningen (UMCG), Groningen, The Netherlands, <sup>2</sup>Dept. of Medical Oncology, Kings College London (KCL), Dept. of Twin Research & Genetic Epidemiology, London, Verenigd Koninkrijk, <sup>3</sup>Dept. of Biomedical Data Sciences, University of Trento, Dept. of Cellular, Computational and Integrative Biology, Povo, Italië, <sup>4</sup>Dept. of Medical Oncology, Kings College London (KCL), Dept. of Twin Research & Genetic Epidemiology, London, Verenigd Koninkrijk, <sup>5</sup>Dept. of Medical Microbiology, University Medical Center Groningen (UMCG), Groningen, Nederland, <sup>6</sup>Dept. of Medical Oncology, University Medical Center Groningen (UMCG), Groningen, The Netherlands.
- 14.24 Increased Risk of Barrett's Esophagus and Esophageal Adenocarcinoma among Individuals with a Positive Family History  
Y Peters<sup>1</sup>, L. Huijbartse<sup>1</sup>, RWM Schrauwen<sup>2</sup>, A.C Tan<sup>3</sup>, RS Van der Post<sup>4</sup>, P.D. Siersema<sup>1</sup>  
<sup>1</sup>Dept. of Gastroenterology and Hepatology, Radboudumc, Nijmegen, Nederland, <sup>2</sup>Dept. of Gastroenterology and Hepatology, Bernhoven, Uden, Nederland, <sup>3</sup>Dept. of Gastroenterology and Hepatology, Canisius Wilhelmina Ziekenhuis, Nijmegen, Nederland, <sup>4</sup>Dept. of Pathology, Radboudumc, Nijmegen, Nederland.
- 14.30 Phase II study of cisplatin and everolimus in patients with metastatic extrapulmonary neuroendocrine carcinoma (NEC)  
S Levy<sup>1</sup>, W.H.M. Verbeek<sup>2</sup>, F.A.L.M. Eskens<sup>3</sup>, D.J.A. de Groot<sup>4</sup>, M.E. van Leerdam<sup>2</sup>, M.E.T. Tesselaar<sup>1</sup>.<sup>1</sup>Dept. of Medical Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands, <sup>2</sup>Dept. of Gastrointestinal Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands, <sup>3</sup>Dept. of Medical Oncology, Erasmus MC Cancer Center, Rotterdam, The Netherlands, <sup>4</sup>Dept. of Medical Oncology, University Medical Center Groningen, Groningen, The Netherlands.
- 14.36 Deep submucosal invasion as independent risk factor for lymph node metastasis in T1 colorectal cancer: a systematic review and meta-analysis  
LW Zwager<sup>1</sup>, B.A.J. Bastiaansen<sup>1</sup>, N. Mostafavi<sup>2</sup>, R. Hompes<sup>3</sup>, V. Barresi<sup>4</sup>, K. Ichimasa<sup>5</sup>, H. Kawachi<sup>6</sup>, I. Machado<sup>7</sup>, T. Masaki<sup>8</sup>, W. Sheng<sup>9</sup>, S. Tanaka<sup>10</sup>, K. Togashi<sup>11</sup>, P. Fockens<sup>1</sup>, L.M.G. Moons<sup>12</sup>, E. Dekker<sup>1</sup> <sup>1</sup>Dept. of Gastroenterology and Hepatology, Amsterdam UMC, Amsterdam, The Netherlands, <sup>2</sup>Dept. of Biostatistics, Amsterdam UMC, Amsterdam, The Netherlands, <sup>3</sup>Dept. of Surgery, Amsterdam UMC, Amsterdam, The Netherlands, <sup>4</sup>Dept. of Public Health, University of Verona, Verona, Italië, <sup>5</sup>Dept. of Gastroenterology and Hepatology, Digestive Disease Center, Showa University Northern Yokohama Hospital, Tsuzuki, Japan, <sup>6</sup>Dept. of Pathology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan, <sup>7</sup>Dept. of Pathology, Instituto Valenciano de Oncología, Valencia, Spanje, <sup>8</sup>Dept. of Surgery, Kyorin University, Tokyo, Japan, <sup>9</sup>Dept. of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China, <sup>10</sup>Dept. of Endoscopy, Hiroshima University Hospital, Hiroshima, Japan, <sup>11</sup>Dept. of Gastroenterology, Aizu Medical Center Fukushima Medical University, Aizuwakamatsu, Japan, <sup>12</sup>Dept. of Gastroenterology and Hepatology, Utrecht University Medical Center, Utrecht, Nederland.

- 14.42      Discovery of a Serum N-Glycan Panel for Early Detection of Pancreatic Cancer in a High-Risk Surveillance Cohort  
D.C.F. Klatte<sup>1</sup>, I.J.M. Levink<sup>2</sup>, R.G.Hanna-Sawires<sup>3</sup>, Y.E.M. de Van der Burgt<sup>4</sup>, K.A. Overbeek<sup>2</sup>, B.D.M. Koopmann<sup>2</sup>, D.L. Cahen<sup>2</sup>, G.M. Fuhler<sup>2</sup>, F.P. Vleggaar<sup>5</sup>, M. Wuhler<sup>4</sup>, R.A.E.M. Tollenaar<sup>3</sup>, B.A. Bonsing<sup>3</sup>, H.F.A. Vasen<sup>1</sup>, M.E. Van Leerdam<sup>1</sup>, M.J. Bruno<sup>2</sup>, W.E. Mesker<sup>3</sup>  
<sup>1</sup>Dept. of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, The Netherlands, <sup>2</sup>Dept. of Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, The Netherlands, <sup>3</sup>Dept. of Surgery, Leiden University Medical Center, Leiden, The Netherlands, <sup>4</sup>Center for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, The Netherlands, <sup>5</sup>Dept. of Gastroenterology and Hepatology, University Medical Center Utrecht, Utrecht, The Netherlands.
- 14.48      Impact of dose-escalated chemoradiotherapy on patient reported outcomes in patients with locally advanced rectal cancer: 2-year follow-up of the randomized RECTAL BOOST trial  
S. Hoendervangers<sup>1</sup>, M.E. Verweij<sup>1</sup>, A.M. Couwenberg<sup>2</sup>, J.P.M. Burbach<sup>3</sup>, W.M.U. van Grevenstein<sup>10</sup>, M.P.W. Intven<sup>1</sup>, H.M. Verkooijen<sup>1</sup>, M. Berbee<sup>4</sup>, J. Buijsen<sup>4</sup>, J. Roodhart<sup>5</sup>, A. Pronk<sup>6</sup>, E.C.J. Consten<sup>7</sup>, A.B. Smits<sup>8</sup>, J.T. Heikens<sup>9</sup>  
<sup>1</sup>Dept. of Radiotherapy, UMC Utrecht, Utrecht, Nederland, <sup>2</sup>Dept. of Radiotherapy, Dutch Cancer Institute, Amsterdam, Nederland, <sup>3</sup>Dept. of Surgery, Medical Centre Leeuwarden, Leeuwarden, Nederland, <sup>4</sup>Dept. of Radiotherapy, MAASTRO, Maastricht, Nederland, <sup>5</sup>Dept. of Internal Medicine, UMC Utrecht, Utrecht, Nederland, <sup>6</sup>Dept. of Surgery, Diaconessenhuis, Utrecht, Nederland, <sup>7</sup>Dept. of Surgery, Meander MC, Amersfoort, Nederland, <sup>8</sup>Dept. of Scientific Research, Antonius hospital, Nieuwegein, Nederland, <sup>9</sup>Dept. of Surgery, Riverland hospital, Tiel, Nederland, <sup>10</sup>Dept. of Surgery, UMC Utrecht, Utrecht, Nederland.
- 14.54      Fluorescence Molecular Endoscopy (FME) using bevacizumab-800CW for the detection of (pre)malignant lesions and evaluation of neoadjuvant chemoradiotherapy in esophageal cancer: the preliminary results  
I. Schmidt<sup>1</sup>, R.Y. Gabriels<sup>1</sup>, W.T.R. Hooghiemstra<sup>1</sup>, X. Zhao<sup>1</sup>, G. Kats-Ugurlu<sup>2</sup>, A.M. van der Waaij<sup>1</sup>, R.Y. Gabriels<sup>1</sup>, J.H. van der Laan<sup>1</sup>, F.A. Dijkstra<sup>3</sup>, J.W. Haveman<sup>3</sup>, B. van Etten<sup>3</sup>, D.J. Robinson<sup>4</sup>, V. Ntziachristos<sup>5</sup>, D. Gorpas<sup>5</sup>, W.B. Nagengast<sup>1</sup>  
<sup>1</sup>Dept. of Gastroenterology and Hepatology, University Medical Center Groningen, Groningen, The Netherlands, <sup>2</sup>Dept. of Pathology and Medical Biology, University Medical Center Groningen, Groningen, The Netherlands, <sup>3</sup>Dept. of Surgery, University Medical Center Groningen, Groningen, The Netherlands, <sup>4</sup>Dept. of Otorhinolaryngology & Head and Neck Surgery, Erasmus Medical Center, Rotterdam, The Netherlands, <sup>5</sup>Center for Translational Cancer Research (TranslaTUM), Technische Universität München, Munich, Germany.
- 15.00      Einde van dit programma onderdeel

Voorzitters: P. van Duijvendijk en D. Roos

- 15.30 Incidence and predictive factors for surgical complications and bile duct injury (BDI) after cholecystectomy for uncomplicated gallstone disease. Results from three prospective multicentre cohort studies.  
*FM Thunnissen<sup>1</sup>, D Comes<sup>1</sup>, PR De Reuver<sup>1</sup>, CSS Latenstein<sup>1</sup>, JPH Drenth<sup>2</sup>, CJHM Van Laarhoven<sup>1</sup>* <sup>1</sup>Dept. of Surgery, Radboudumc, Nijmegen, Nederland, <sup>2</sup>Dept. of Gastroenterology, Radboudumc, Nijmegen, Nederland.
- 15.33 The definition and outcomes of oligometastatic esophagogastric cancer: a systematic review and meta-analysis  
*T. E. Kroese<sup>1</sup>, P.S.N. van Rossum<sup>2</sup>, H.W.M. van Laarhoven<sup>3</sup>, R van Hillegersberg<sup>1</sup>* <sup>1</sup>Dept. of Surgery, UMC Utrecht, Utrecht, The Netherlands, <sup>2</sup>Dept. of Radiation Oncology, UMC Utrecht, Utrecht, The Netherlands, <sup>3</sup>Dept. of Medical Oncology, Amsterdam University Medical Centers, Amsterdam, The Netherlands.
- 15.36 Management of Pancreatic Fistula and Biliary Leakage after pancreatoduodenectomy through Percutaneous Transhepatic Biliary Drainage  
*AC Henry<sup>1</sup>, FJ Smits<sup>1</sup>, K van Lienden<sup>2</sup>, DAF van den Heuvel<sup>2</sup>, OR Busch<sup>3</sup>, OM van Delden<sup>4</sup>, M van Leersum<sup>2</sup>, MJL van Strijen<sup>2</sup>, JA Vos<sup>2</sup>, WW te Riele<sup>1</sup>, IQ Molenaar<sup>1</sup>, MG Besselink<sup>3</sup>, HC van Santvoort<sup>1</sup>* <sup>1</sup>Dept. of Gastrointestinal Surgery, Regional Academic Cancer Center Utrecht, Utrecht, Nederland, <sup>2</sup>Dept. of Radiology, St. Antonius Hospital, Nieuwegein, Nederland, <sup>3</sup>Dept. of Gastrointestinal Surgery, Amsterdam University Medical Center, Amsterdam, Nederland, <sup>4</sup>Dept. of Radiology, Amsterdam University Medical Center, Amsterdam, Nederland.
- 15.39 Pancreas-sparing duodenectomy for advanced duodenal polyposis in patients with familial adenomatous polyposis: short and long-term outcomes  
*A.S. Aelvoet<sup>1</sup>, B.A.J. Bastiaansen<sup>1</sup>, O.R.C. Busch<sup>2</sup>, E Dekker<sup>1</sup>* <sup>1</sup>Dept. of Gastroenterology and Hepatology, Amsterdam UMC, location AMC, Amsterdam, The Netherlands, <sup>2</sup>Dept. of Surgery, Amsterdam UMC, location AMC, Amsterdam, The Netherlands.
- 15.42 Delaying surgery to achieve a complete response after neoadjuvant chemoradiotherapy for rectal cancer: at what “cost”? A single institution analysis of hospital costs, surgical and oncological outcomes.  
*VM Meyer<sup>1</sup>, RR Meuzelaar<sup>1</sup>, Y Schoenaker<sup>1</sup>, JW de Groot<sup>2</sup>, E de Boer<sup>3</sup>, O Reerink<sup>4</sup>, WH de Vos tot Nederveen Cappel<sup>5</sup>, GL Beets<sup>6</sup>, HL van Westreenen<sup>1</sup>* <sup>1</sup>Dept. of Surgery, Isala klinieken, Zwolle, Nederland, <sup>2</sup>Dept. of Medical Oncology, Isala klinieken, Zwolle, Nederland, <sup>3</sup>Dept. of Radiology, Isala klinieken, Zwolle, Nederland, <sup>4</sup>Dept. of Radiotherapy, Isala klinieken, Zwolle, Nederland, <sup>5</sup>Dept. of Gastroenterology and Hepatology, Isala klinieken, Zwolle, Nederland, <sup>6</sup>Dept. of Surgery, NKI, Antoni van Leeuwenhoek ziekenhuis, Amsterdam, Nederland.
- 15.45 Postponing surgery to optimise patients with acute right-sided obstructing colon cancer - a pilot study  
*J.R.E. Boeding<sup>1</sup>, I.E.Cuperus<sup>2</sup>, A.M. Rijken<sup>2</sup>, R.M.P.H. Crolla<sup>2</sup>, C. Verhoef<sup>3</sup>, P.D. Gobardhan<sup>2</sup>, J.M.J.Schreinemakers<sup>2</sup>* <sup>1</sup>Dept. of Surgery, Amphibia ziekenhuis, Breda, Nederland, <sup>2</sup>Dept. of Surgery, Amphibia Hospital, Breda, Nederland, <sup>3</sup>Dept. of Surgery, Erasmus MC, Rotterdam, The Netherlands.

Woensdag 17 maart 2021

- 15.48 Delayed surgery after neoadjuvant treatment for rectal cancer does not lead to regret, impaired quality of life or worry for cancer.  
VM Meyer<sup>1</sup>, RR Meuzelaar<sup>1</sup>, Y Schoenaker<sup>1</sup>, JW de Groot<sup>2</sup>, E de Boer<sup>3</sup>, O Reerink<sup>4</sup>, WH de Vos tot Nederveen Cappel<sup>5</sup>, GL Beets<sup>6</sup>, HL van Westreenen<sup>1</sup> <sup>1</sup>Dept. of Surgery, Isala klinieken, Zwolle, Nederland, <sup>2</sup>Dept. of Medical Oncology, Isala klinieken, Zwolle, Nederland, <sup>3</sup>Dept. of Radiology, Isala klinieken, Zwolle, Nederland, <sup>4</sup>Dept. of Radiotherapy, Isala klinieken, Zwolle, Nederland, <sup>5</sup>Dept. of Gastroenterology and Hepatology, Isala klinieken, Zwolle, Nederland, <sup>6</sup>Dept. of Surgery, NKI, Antoni van Leeuwenhoek ziekenhuis, Amsterdam, Nederland.
- 15.51 Long-term Outcome of Radical Excision vs. Phenolisation of the Sinus Tract in Primary Sacrococcygeal Pilonidal Sinus Disease; A Randomized Controlled Trial  
A.A. Pronk<sup>1</sup>, M.J. Vissink<sup>1</sup>, N. Smakman<sup>2</sup>, E.J.B. Furnee<sup>3</sup>, <sup>1</sup>Dept. of Surgery, Diakonessenhuis Utrecht, Utrecht, <sup>2</sup>Dept. of Surgery, Diakonessenhuis, Utrecht, <sup>3</sup>Dept. of Surgery, University Medical Centre Groningen, Groningen, The Netherlands.
- 15.54 Chest X-ray in the follow-up of colorectal carcinoma: added value?  
E.G.M. Steenhuis<sup>1</sup>, I.J.H. Schoenaker<sup>1</sup>, R.M. Brohet<sup>1</sup>, J.W.B. De Groot<sup>2</sup>, H.L. Van Westreenen<sup>3</sup>, W.H. Vos tot Nederveen Cappel<sup>1</sup> <sup>1</sup>Dept. of Gastroenterology and Hepatology, Isala, Zwolle, Nederland, <sup>2</sup>Dept. of Internal Medicine, Isala, Zwolle, Nederland, <sup>3</sup>Dept. of Gastrointestinal Oncology, Isala, Zwolle, Nederland.
- 15.57 Discussie  
Alle sprekers
- Invited speaker**
- 16.15 No guts, some glory  
Drs. S. Hofker, chirurg, Universitair Medisch Centrum Groningen
- 16.30 Einde van dit programma onderdeel



Voorzitters: L.J.A.C. Hawinkels en M.E. Wildenberg

- 08.30 Effect of host genetics on the gut microbiome in 7,738 participants of the Dutch Microbiome Project  
S.H. Hu<sup>2</sup>, E.A.L. Lopera-Maya<sup>3</sup>, A.K. Kurilshikov<sup>3</sup>, A.G. Van der Graaf<sup>3</sup>, S.A. Andreu- Sánchez<sup>3</sup>, L.C. Chen<sup>4</sup>, A.V. Vich Vila<sup>2</sup>, R.G. Gacesa<sup>2</sup>, T.S. Sinha<sup>3</sup>, V.C. Collij<sup>2</sup>, M.A.Y.K. Klaassen<sup>2</sup>, L.A.B. Bolte<sup>2</sup>, M.F.B.G. Brandao Gois<sup>3</sup>, P.B.T.N. Neerincx<sup>3</sup>, M.A.S. Swertz<sup>5</sup>, H.J.M.H. Harmsen<sup>6</sup>, C.W. Wijmenga<sup>3</sup>, J.F. Fu<sup>4</sup>, A.Z. Zhernakova<sup>3</sup>, S.S. Sanna<sup>3</sup>, R.W. Weersma<sup>2</sup>, <sup>1</sup>Dept. of Gastroenterology and Hepatology, University of Groningen and University Medical Center Groningen, Nederland, <sup>2</sup>Dept. of Gastroenterology and Hepatology, University of Groningen and University Medical Center Groningen, Groningen, Nederland, <sup>3</sup>Dept. of Clinical Genetics, University of Groningen and University Medical Center Groningen, Groningen, Nederland, <sup>4</sup>Dept. of Pediatrics, University of Groningen and University Medical Center Groningen, Groningen, Nederland, <sup>5</sup>Dept. of Clinical Genetics, University of Groningen and University Medical Center Groningen, Groningen, Nederland, <sup>6</sup>Dept. of Medical Microbiology, University of Groningen and University Medical Center Groningen, Groningen, Nederland.
- 08.35 Human intestinal (regulatory) T cells show profound adaptation to the microenvironment and alteration of phenotype during inflammation in Crohn's disease patients  
L. Lutter<sup>1</sup>, E. Brand<sup>2</sup>, B. Roosenboom<sup>3</sup>, D. Hoytema van Konijnenburg<sup>4</sup>, M. Van der Wal<sup>1</sup>, C. Horjus-Talabur Horje<sup>3</sup>, B. Oldenburg<sup>2</sup>, F. Van Wijk<sup>1</sup> <sup>1</sup>Centre for Translational Immunology, Universitair Medisch Centrum Utrecht, Utrecht, Nederland, <sup>2</sup>Dept. of Gastroenterology and Hepatology, Universitair Medisch Centrum Utrecht, Utrecht, Nederland, <sup>3</sup>Dept. of Gastroenterology and Hepatology, Rijnstate ziekenhuis, Arnhem, Nederland, <sup>4</sup>Dept. of Pediatrics, Harvard Medical School, Boston, Verenigde Staten.
- 08.40 Fecal water from Crohn's disease patients: high mucin degradation, but no epithelial barrier disruption in vitro  
H.E.F. Becker<sup>1</sup>, N. Kameli<sup>2</sup>, A. Rustichelli<sup>1</sup>, B.A.M. Heijns<sup>1</sup>, F. Stassen<sup>2</sup>, J. Penders<sup>2</sup>, D.M.A.E. Jonkers<sup>1</sup> <sup>1</sup>Dept. of Gastroenterology and Hepatology, Maastricht University, Maastricht, Nederland, <sup>2</sup>Dept. of Medical Microbiology, Maastricht University, Maastricht, Nederland.

### Key note lecture

- 08.45 Cellular microbiology of the crypt ecosystem: deciphering microbe-stem cell interactions in health and disease  
Prof. Philippe Sansonetti, Institut Pasteur, Paris
- 09.15 Cross-presentation by cancer-associated fibroblasts suppresses anti-tumor T cell immunity and is enhanced by upregulation of the lysosomal protease Cathepsin S in human colorectal cancer.  
L.J.A.C. Hawinkels<sup>1</sup>, E.M.E. Verdegaa<sup>2</sup>, J. Hardwick<sup>1</sup> <sup>1</sup>Dept. of Gastroenterology and Hepatology, LUMC, Leiden, The Netherlands, <sup>2</sup>Dept. of Medical Oncology, LUMC, Leiden, The Netherlands.
- 09.20 Targeting G1TR enhances human tumour-infiltrating T cell functionality in mismatch repair proficient primary colorectal carcinoma and liver metastases  
Y.S. Rakké<sup>1</sup>, D. Sprengers<sup>2</sup>, J. Kwekkeboom<sup>2</sup>, L. Campos Carrascosa<sup>2</sup>, A.A. van Beek<sup>2</sup>, V. de Rooter<sup>2</sup>, M. Doukas<sup>3</sup>, S. ter Borg<sup>4</sup>, P.G. Doornebosch<sup>5</sup>, M. Vermaas<sup>5</sup>, E. van der Harst<sup>6</sup>, P.P.L.O. Coene<sup>6</sup>, D.J. Grünhage<sup>1</sup>, C. Verhoef<sup>1</sup>, J.N.M. IJzermans<sup>1</sup> <sup>1</sup>Dept. of Surgery, Erasmus MC - University Medical Center, Rotterdam, The Netherlands, <sup>2</sup>Dept. of Gastroenterology and

Donderdag 18 maart 2021

Hepatology, Erasmus MC - University Medical Center, Rotterdam, <sup>3</sup>Dept. of Pathology, Erasmus MC - University Medical Center, Rotterdam, <sup>4</sup>Dept. of Pathology, Pathan BV, Rotterdam, <sup>5</sup>Dept. of Surgery, IJsselland Hospital, Capelle aan den IJssel, The Netherlands, <sup>6</sup>Dept. of Surgery, Maasstad Hospital, Rotterdam, The Netherlands.

- 09.25 Prevalence and Clinical Characteristic of Autoimmune Gastritis in Patients with Intestinal Metaplasia  
X.P. Guo<sup>1</sup>, M.C. Mommersteed<sup>1</sup>, M. Tokat<sup>1</sup>, M. Scherurs<sup>2</sup>, N. Erler<sup>3</sup>, M. Peppelenbosch<sup>1</sup>, M. Spaander<sup>1</sup>, G. Fuhler<sup>1</sup> <sup>1</sup>Dept. of Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, <sup>2</sup>Dept. of Immunopathology, Erasmus University Medical Center, Rotterdam, <sup>3</sup>Dept. of Biostatistics, Erasmus University Medical Center, Rotterdam, Nederland.
- 09.30 Einde van dit programma onderdeel, mogelijkheid tot volgen netwerksessie tot 10.00

---

### Symposium Nederlandse Vereniging voor Hepatologie

---

Studio I

Voorzitters: J.P.H. Drenth en E.M.M. Kuiper

- 10.00 Behandeling van Hepatitis C anno 2021: de laatste inzichten  
M. van Dijk, arts-onderzoeker, Radboudumc, Nijmegen en  
Dr. H. van Soest, MDL-arts, Haaglanden Medisch Centrum, Den Haag
- 10.30 Ascites: de behandelopties  
Dr. A.J.P. van der Meer, MDL-arts, Erasmus MC, Rotterdam en  
Dr. R.B. Takkenberg, Amsterdam UMC, loc. AMC
- 11.00 Afsluiting programma onderdeel

---

### Symposium NVMDL

---

Studio I

Voorzitter: E. Dekker en V.M.C.W. Spaander

#### Symposium Coloscopie surveillance

- 11.30 Inleiding  
Prof. dr. E. Dekker, MDL-arts, Amsterdam UMC, Amsterdam
- 11.35 Surveillance adenomen  
Prof. dr. M.E. van Leerdam, MDL-arts, NKI/AvL en LUMC
- 11.50 Surveillance SSLs  
Dr. Y. Hazewinkel, MDL-arts, Radboudumc, Nijmegen
- 12.05 Surveillance na CRC  
Dr. A.M. van Berkel, MDL-arts, Noordwest Ziekenhuisgroep, Alkmaar
- 12.15 Start/stopcriteria surveillance (oa leeftijd) en andere discussiepunten  
Dr. I. Lansdorp-Vogelaar, iMGZ, Erasmus MC, Rotterdam
- 12.30 Afsluiting programma onderdeel

---

**Symposium – Sectie Gastrointestinale Endoscopie**

**Studio I**

Voorzitters: *L.M.G. Moons en M. van Schaik*

**Symposium: Less is more**

- 14.00 "Less or More": gastroscopieën; wat is doelmatig?  
*Prof. dr. J.P.H. Drenth, MDL-arts, Radboudumc, Nijmegen*
- 14.20 "Less is More" in EUS/ERCP  
*Dr. J.W. Poley, MDL-arts, Erasmus MC, Rotterdam*
- 14.40 "Less is More" in Endoscopy  
*Prof. dr. J.J.G.H.M. Bergman, MDL-arts, Amsterdam UMC, loc. AMC, Amsterdam*
- 15.00 Einde van dit programma onderdeel

---

**Symposium – Sectie Kinder-MDL**

**Studio I**

Voorzitters: *V.M. Wolters en F.D.M. van Schaik*

**Symposium: Jong gekregen, oud gehouden**

- 15.30 FAP: stap voor stap  
Zorg voor adolescenten met familiale adenomateuze polyposis  
*Dr. A. van den Berg kinderarts-MDL, WKZ/UMCU, Utrecht*  
*Dr. M.C.A. van Kouwen MDL-arts, Radboudumc, Nijmegen*
- 16.00 Primair Scleroserende Cholangitis zorg anno 2021: one size fits all ages?  
*Dr. B.G.P. Koot kinderarts-MDL, Amsterdam UMC, Amsterdam*  
*Prof. dr. C.Y. Ponsioen MDL-arts, Amsterdam UMC, Amsterdam*
- 16.30 Einde van dit programma onderdeel, mogelijkheid tot volgen netwerksessie tot 17.00

Voorzitters: *C.J. van der Woude en R. van Hillegersberg*

17.00 Bekendmaking Gastrostartsubsidies voorjaar 2021

17.10 **Uitreiking NVGE Gastrointestinale Proefschriftprijs 2020 en 2021 door voorzitter van de jury gevolgd door voordrachten door de prijswinnaars**

Uitreiking proefschriftprijs 2020 gevolgd door voordracht

Uitreiking proefschriftprijs 2021 gevolgd door voordracht

17.30 Invited speaker: to be announced

18.00 Afsluiting programma onderdeel

Voorzitters: J.P.H. Drenth en E.M.M. Kuiper

- 08.30 Ursodeoxycholic acid for the prevention of symptomatic gallstone disease after bariatric surgery: a multicenter, randomized, placebo-controlled, double-blind superiority trial (UPGRADE trial)  
S. Haal<sup>1</sup>, M.S.S. Guman<sup>2</sup>, T.C.C. Boerlage<sup>3</sup>, Y.I.Z. Acherman<sup>4</sup>, L.M. De Brauw<sup>4</sup>, S. Bruin<sup>5</sup>, S.M.M. De Castro<sup>6</sup>, J.E. van Hoof<sup>7</sup>, A.W.J.M. van de Laar<sup>4</sup>, D.E. Moes<sup>8</sup>, M. Schouten<sup>9</sup>, R. Schouten<sup>9</sup>, E.J. Van Soest<sup>10</sup>, R.N. Van Veen<sup>6</sup>, C.E.E. De Vries<sup>6</sup>, P. Fockens<sup>1</sup>, M.G.W. Dijkgraaf<sup>11</sup>, V.E.A. Gerdes<sup>2</sup>, R.P. Voermans<sup>1</sup> <sup>1</sup>Dept. of Gastroenterology and Hepatology, Amsterdam UMC locatie AMC, Amsterdam, Nederland, <sup>2</sup>Dept. of Internal Medicine, Amsterdam UMC locatie AMC, Amsterdam, Nederland, <sup>3</sup>Dept. of Gastroenterology, Sint Antonius Ziekenhuis, Nieuwegein, Nederland, <sup>4</sup>Dept. of Surgery, Spaarne Gasthuis, Hoofddorp, Nederland, <sup>5</sup>Dept. of Surgery, Spaarne Gasthuis, Hoofddorp, Nederland, <sup>6</sup>Dept. of Surgery, OLVG, Amsterdam, Nederland, <sup>7</sup>Dept. of Gastroenterology and Hepatology, LUMC, Leiden, Nederland, <sup>8</sup>Dept. of Surgery, Dijklander ziekenhuis, Hoorn, Nederland, <sup>9</sup>Dept. of Surgery, Flevoziekenhuis, Almere, Nederland, <sup>10</sup>Dept. of Gastroenterology, Spaarne Gasthuis, Hoofddorp, Nederland, <sup>11</sup>Dept. of Epidemiology and Biostatistics, Amsterdam UMC locatie AMC, Amsterdam, Nederland.
- 08.36 Liver decompensation as late complication in HCC patients with long term responses following selective internal radiation therapy.  
D.J. van Doorn<sup>1</sup>, P. Hendriks<sup>2</sup>, M.C. Burgmans<sup>2</sup>, D.D.D. Rietbergen<sup>3</sup>, M. Coenraad<sup>4</sup>, O.M. van Delden<sup>5</sup>, R.J. Bennink<sup>5</sup>, T.A. Labeur<sup>1</sup>, H.J. Klümpen<sup>6</sup>, F.A.L.M. Eskens<sup>7</sup>, A. Moelker<sup>8</sup>, E. Vegt<sup>9</sup>, D. Sprengers<sup>10</sup>, N. Mostafavi<sup>11</sup>, J. Ijzermans<sup>12</sup>, R.B. Takkenberg<sup>1</sup> <sup>1</sup>Dept. of Gastroenterology and Hepatology, Amsterdam UMC, Universiteit van Amsterdam, Amsterdam, Nederland, <sup>2</sup>Dept. of Radiology, LUMC, Leiden, Nederland, <sup>3</sup>Dept. of Radiology and Nuclear Medicine, LUMC, Leiden, Nederland, <sup>4</sup>Dept. of Gastroenterology and Hepatology, LUMC, Leiden, Nederland, <sup>5</sup>Dept. of Radiology and Nuclear Medicine, Amsterdam UMC, Universiteit van Amsterdam, Amsterdam, Nederland, <sup>6</sup>Dept. of Medical Oncology, Amsterdam UMC, Universiteit van Amsterdam, Amsterdam, Nederland, <sup>7</sup>Dept. of Medical Oncology, Erasmus Medical Center, Rotterdam, Nederland, <sup>8</sup>Dept. of Radiology, Erasmus Medical Center, Rotterdam, Nederland, <sup>9</sup>Dept. of Radiology and Nuclear Medicine, Erasmus Medical Center, Rotterdam, Nederland, <sup>10</sup>Dept. of Gastroenterology and Hepatology, Erasmus Medical Center, Rotterdam, Nederland, <sup>11</sup>Dept. of Biostatistics, Amsterdam UMC, Universiteit van Amsterdam, Amsterdam, Nederland, <sup>12</sup>Dept. of Surgery, Erasmus Medical Center, Rotterdam, Nederland.
- 08.42 The alteration of gut microbiome in liver transplantation: first results from the TransplantLines Biobank and Cohort study  
Y. Li<sup>1</sup>, S. Hu<sup>1</sup>, C. Swarte<sup>1</sup>, G. Ranko<sup>1</sup>, A. Vich Vila<sup>1</sup>, R. Douwes<sup>1</sup>, H. Harmsen<sup>2</sup>, B. Jansen<sup>1</sup>, V. De Meijer<sup>3</sup>, J. Fu<sup>4</sup>, E.A.M. Festen<sup>1</sup>, S. Bakker<sup>5</sup>, H. Blokzijl<sup>1</sup>, R. Weersma<sup>1</sup> <sup>1</sup>Dept. of Gastroenterology and Hepatology, University Medical Center of Groningen, Groningen, Nederland, <sup>2</sup>Dept. of Medical Microbiology, University Medical Center of Groningen, Groningen, Nederland, <sup>3</sup>Dept. of Surgery, University Medical Center of Groningen, Groningen, Nederland, <sup>4</sup>Dept. of Pediatrics, University Medical Center of Groningen, Groningen, Nederland, <sup>5</sup>Dept. of Neurosurgery, University Medical Center of Groningen, Groningen, Nederland.
- 08.48 Hepatitis C Elimination in the Netherlands (CELINE): nationwide retrieval of lost to follow-up patients with chronic hepatitis C  
C.J. Isfordink<sup>1</sup>, M. van Dijk<sup>2</sup>, S.M. Brakenhoff<sup>3</sup>, J.E. Arends<sup>4</sup>, R.J. de Knegt<sup>3</sup>, M. van der Valk<sup>5</sup>, J.P.H. Drenth<sup>2</sup> <sup>1</sup>Dept. of Gastroenterology and Hepatology, University Medical Centre Utrecht, Utrecht, The Netherlands, <sup>2</sup>Dept. of Gastroenterology and Hepatology, Radboud University Medical Centre, Nijmegen, The Netherlands, <sup>3</sup>Dept. of Gastroenterology and Hepatology, Erasmus Medical Center, Rotterdam, The Netherlands, <sup>4</sup>Dept. of Infectious Diseases, University

Donderdag 18 maart 2021

Medical Centre Utrecht, Utrecht, The Netherlands, <sup>5</sup>Dept. of Infectious Diseases, Amsterdam University Medical Centers, Amsterdam, The Netherlands.

- 08.54 End of treatment HBsAg, HBcrAg and HBV RNA levels predict risk of off-treatment ALT flares in patients with chronic hepatitis B  
S.M. Brakenhoff<sup>1</sup>, R.J. de Knecht<sup>1</sup>, M.J.H. van Campenhout<sup>1</sup>, A.A. van der Eijk<sup>2</sup>, W.P. Brouwer<sup>1</sup>, F. van Bömmel<sup>3</sup>, A. Boonstra<sup>1</sup>, B.E. Hansen<sup>4</sup>, T. Berg<sup>3</sup>, H.L.A. Janssen<sup>4</sup>, R.A. De Man<sup>1</sup>, M.J. Sonneveld<sup>1</sup> <sup>1</sup>Dept. of Gastroenterology and Hepatology, Erasmus MC, University Medical Center, Rotterdam, Rotterdam, The Netherlands, <sup>2</sup>Dept. of Viroscience, Erasmus MC, University Medical Center, Rotterdam, Rotterdam, The Netherlands, <sup>3</sup>Dept. of Hepatology, Leipzig University Medical Center, Leipzig, Duitsland, <sup>4</sup>Toronto Center for Liver Disease, Toronto General Hospital, Toronto, Canada.
- 09.00 Autoimmune hepatitis – primary biliary cholangitis variant often treated outside Paris criteria with similar results  
M. Biewenga<sup>1</sup>, J.P.H. Drenth<sup>2</sup>, X. Verhelst<sup>3</sup>, A.J.P. van der Meer<sup>4</sup>, Y.S. de Boer<sup>5</sup>, G. Bouma<sup>5</sup>, A.C. Poen<sup>6</sup>, R.C. Verdonk<sup>7</sup>, A.P. van der Berg<sup>8</sup>, J.T. Brouwer<sup>9</sup>, T. Vanwolleghem<sup>10</sup>, W.J. Lammers<sup>4</sup>, A. Farina Sarasqueta<sup>11</sup>, J. Verheij<sup>11</sup>, T. Roskams<sup>12</sup>, B. van Hoek<sup>1</sup> <sup>1</sup>Dept. of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, Nederland, <sup>2</sup>Dept. of Gastroenterology and Hepatology, Radboud University Medical Center, Nijmegen, Nederland, <sup>3</sup>Dept. of Gastroenterology and Hepatology, UZ Gent, Gent, België, <sup>4</sup>Dept. of Gastroenterology and Hepatology, Erasmus MC, Rotterdam, Nederland, <sup>5</sup>Dept. of Gastroenterology and Hepatology, Amsterdam UMC locatie VUmc, Amsterdam, Nederland, <sup>6</sup>Dept. of Gastroenterology and Hepatology, Isala clinics, Zwolle, Nederland, <sup>7</sup>Dept. of Gastroenterology and Hepatology, Sint Antonius Hospital, Nieuwegein, Nederland, <sup>8</sup>Dept. of Gastroenterology and Hepatology, University Medical Center Groningen, Groningen, Nederland, <sup>9</sup>Dept. of Gastroenterology and Hepatology, Reinier de Graaf Gasthuis, Delft, Nederland, <sup>10</sup>Dept. of Gastroenterology and Hepatology, UZ Antwerpen, Antwerpen, België, <sup>11</sup>Dept. of Pathology, Amsterdam UMC locatie AMC, Amsterdam, Nederland, <sup>12</sup>Dept. of Pathology, UZ Leuven, Leuven, België.
- 09.06 Pearl studie  
Dr. R.B. Takkenberg, Amsterdam UMC, loc. AMC
- 09.18 Camaro studie  
R.J.A.L.M. Snijders, Radboudumc, Nijmegen
- 09.30 Einde van dit programma onderdeel, mogelijkheid tot volgen netwerksessie tot 10.00

Voorzitters: L.J.A.C. Hawinkels en M.E. Wildenberg

10.00 **Battle junior researcher award**

10.15 Mass cytometry reveals networks of tissue resident immune cell clusters associated with inflammation in IBD  
*Prof. dr. F. Koning, Hoogleraar Immunologie, Leids Universitair Medisch Centrum*

10.45 Single cell RNA sequencing identifies distinct intestinal inflammation patterns in primary sclerosing cholangitis associated colitis compared to ulcerative colitis  
*A. Bangma<sup>1</sup>, W.T.C. Uniken Venema<sup>1</sup>, M.G.P. van der Wijst<sup>2</sup>, G. Katz<sup>3</sup>, A. Vich Villa<sup>1</sup>, R.K. Weersma<sup>4</sup>, E.A.M. Festen<sup>1</sup>* <sup>1</sup>Dept. of Gastroenterology and Hepatology, Universitair Medisch Centrum Groningen, Rijksuniversiteit Groningen, Groningen, Nederland, <sup>2</sup>Dept. of Genetics, Universitair Medisch Centrum Groningen, Rijksuniversiteit Groningen, Groningen, Nederland, <sup>3</sup>Dept. of Pathology, Universitair Medisch Centrum Groningen, Groningen, Nederland, <sup>4</sup>Dept. of Gastroenterology and Hepatology, Universitair Medisch Centrum Groningen, Groningen, Nederland.

10.51 Homeostatic function and inflammatory activation of ileal CD8<sup>+</sup> tissue-resident (CD69+CD103<sup>+</sup>) T-cells is dependent on mucosal location  
*L. Lutter<sup>1</sup>, B. Roosenboom<sup>2</sup>, E. Brand<sup>3</sup>, J. Ter Linde<sup>3</sup>, E. Van Lochem<sup>4</sup>, B. Oldenburg<sup>3</sup>, C. Horjus-Talabur Horje<sup>2</sup>, F. Van Wijk<sup>1</sup>* <sup>1</sup>Centre for Translational Immunology, Universitair Medisch Centrum Utrecht, Utrecht, Nederland, <sup>2</sup>Dept. of Gastroenterology and Hepatology, Rijnstate ziekenhuis, Arnhem, Nederland, <sup>3</sup>Dept. of Gastroenterology and Hepatology, Universitair Medisch Centrum Utrecht, Utrecht, Nederland, <sup>4</sup>Dept. of Microbiology and Immunology, Rijnstate ziekenhuis, Arnhem, Nederland.

10.57 Activated, cytotoxic CD27+PD1<sup>+</sup> CD8-T cells in RCDII duodenum  
*T. de Dieckman<sup>1</sup>, M. Schreurs<sup>2</sup>, A.M.E.T.A de Mahfouz<sup>3</sup>, G. Bouma<sup>4</sup>, F. de Koning<sup>1</sup>* <sup>1</sup>Dept. of Immunology, LUMC, Leiden, Nederland, <sup>2</sup>Dept. of Immunohematology and Blood Transfusion, LUMC, Leiden, The Netherlands, <sup>3</sup>Dept. of Human Genetics, LUMC, Leiden, The Netherlands, <sup>4</sup>Dept. of Gastroenterology and Hepatology, Amsterdam UMC, location VUmc, Amsterdam, The Netherlands.

**Battle winner announcement**

11.00 Einde van dit programma onderdeel

11.30 uur– 12.30 uur

**Thema: IBS**

Deze sessies – waarvoor tevoren moet worden ingeschreven - worden verzorgd door:  
Prof. dr. A.A.M. Masclee, MDL-arts, MUMC, Maastricht  
Dr. LA. van der Waaij, MDL-arts, Martini ziekenhuis, Groningen

12.30 Einde van dit programma onderdeel, mogelijkheid tot volgen netwerksessie tot 14.00

---

**Abstractsessie – Sectie Inflammatoire Darmziekten**

**Studio 2**

---

Voorzitters: A.G.L. Bodelier en S.F.G. Jeuring

14.00 Ustekinumab for Crohn's Disease: Two-Year Results of the Initiative on Crohn and Colitis (ICC) Registry, a Nationwide Prospective Observational Cohort Study  
T.S. Straatmijer<sup>1</sup>, V.B.C. Biemans<sup>2</sup>, F. Hoentjen<sup>3</sup>, P.W.J. Maljaars<sup>4</sup>, B Oldenburg<sup>2</sup>, J Haans<sup>5</sup>, K.H.N. de Boer<sup>6</sup>, C.I.J. Ponsioen<sup>7</sup>, M. C. Visschedijk<sup>8</sup>, J.M. Jansen<sup>9</sup>, R.L. West<sup>10</sup>, A.G.L. Bodelier<sup>11</sup>, C.J. van der Woude<sup>12</sup>, W.A. van Dop<sup>3</sup>, A.C. de Vries<sup>13</sup>, G Dijkstra<sup>8</sup>, S van der Marel<sup>14</sup>, M.J. Pierik<sup>5</sup>, M. Duijvestein<sup>7</sup>, A. E. van der Meulen<sup>4</sup> <sup>1</sup>Dept. of Gastroenterology and Hepatology, Amsterdam UMC, Amsterdam, The Netherlands, <sup>2</sup>Dept. of Gastroenterology and Hepatology, UMCU, Utrecht, The Netherlands, <sup>3</sup>Dept. of Gastroenterology and Hepatology, Radboudumc, Nijmegen, The Netherlands, <sup>4</sup>Dept. of Gastroenterology and Hepatology, LUMC, Leiden, The Netherlands, <sup>5</sup>Dept. of Gastroenterology and Hepatology, MUMC, Maastricht, The Netherlands, <sup>6</sup>Dept. of Gastroenterology and Hepatology, Amsterdam UMC, locatie VUmc, Amsterdam, The Netherlands, <sup>7</sup>Dept. of Gastroenterology and Hepatology, Amsterdam UMC, locatie AMC, Amsterdam, The Netherlands, <sup>8</sup>Dept. of Gastroenterology and Hepatology, UMCG, Groningen, The Netherlands, <sup>9</sup>Dept. of Gastroenterology and Hepatology, OLVG, Amsterdam, The Netherlands, <sup>10</sup>Dept. of Gastroenterology and Hepatology, Franciscus Gasthuis & Vlietland, Rotterdam, The Netherlands, <sup>11</sup>Dept. of Gastroenterology and Hepatology, Amphia, Breda, The Netherlands, <sup>12</sup>Dept. of Gastroenterology, Erasmus MC, Rotterdam, The Netherlands, <sup>13</sup>Dept. of Gastroenterology and Hepatology, Erasmus MC, Rotterdam, The Netherlands, <sup>14</sup>Dept. of Gastroenterology and Hepatology, HMC, Den Haag, The Netherlands.

14.06 Acceptance and perceived control are independently associated with quality of life in inflammatory bowel disease: introduction of a new segmentation model  
L.W. van Erp<sup>1</sup>, J. van Gerven<sup>2</sup>, S. de Bloem<sup>3</sup>, M.J.M. Groenen<sup>2</sup>, P.J. Wahab<sup>4</sup> <sup>1</sup>Dept. of Gastroenterology and Hepatology, Rijnstate ziekenhuis, Arnhem, Nederland, <sup>2</sup>Dept. of Gastroenterology and Hepatology, Rijnstate Hospital, Arnhem, The Netherlands, <sup>3</sup>Center for Marketing & Supply Chain Management, Nyenrode Business University, Breukelen, The Netherlands, <sup>4</sup>Dept. of Gastroenterology and Hepatology, Nyenrode Business University, Breukelen, The Netherlands.

14.12 Exclusive enteral nutrition or prednisolone induction treatment: clinical and endoscopic evaluation of new-onset luminal paediatric Crohn's disease.  
MME Jongsma<sup>1</sup>, MA Cozijnsen<sup>1</sup>, M van Pieteron<sup>1</sup>, TGJ de Meij<sup>2</sup>, O.F Norbruis<sup>3</sup>, M Groeneweg<sup>4</sup>, VM Wolters<sup>5</sup>, HM van Wering<sup>6</sup>, I Hojsak<sup>7</sup>, KL Kolho<sup>8</sup>, MP van Wijk<sup>1</sup>, S Teklenburg-Roord<sup>3</sup>, JC Escher<sup>1</sup>, L de Ridder<sup>1</sup> <sup>1</sup>Dept. of Pediatric Gastroenterology Hepatology and Nutrition, Erasmus MC University Medical Center-Sophia Children's Hospital,



Rotterdam, Nederland, <sup>2</sup>Dept. of Pediatric Gastroenterology Hepatology and Nutrition, Amsterdam UMC-Emma children's hospital, Amsterdam, Nederland, <sup>3</sup>Dept. of Pediatric Gastroenterology Hepatology and Nutrition, Isala ziekenhuis, Zwolle, Nederland, <sup>4</sup>Dept. of Pediatrics, Maastad ziekenhuis, Rotterdam, Nederland, <sup>5</sup>Dept. of Pediatric Gastroenterology Hepatology and Nutrition, Utrecht UMC- Wilhelmina kindeziekenhuis, Utrecht, Nederland, <sup>6</sup>Dept. of Pediatrics, Amphia ziekenhuis, Breda, Nederland, <sup>7</sup>Dept. of Pediatric Gastroenterology Hepatology and Nutrition, Zagreb children's hospital, Zagreb, Kroatië, <sup>8</sup>Dept. of Pediatric Gastroenterology Hepatology and Nutrition, Tampere University Hospital, Helsinki, Finland.

- 14.18 De-escalation of biological therapy in inflammatory bowel disease patients following prior escalation  
P.W.A. Thomas<sup>1</sup>, L.J.T. Smits<sup>1</sup>, M. Te Groen<sup>1</sup>, R.L. West<sup>2</sup>, M.G.V.M. Russel<sup>3</sup>, J.M. Jansen<sup>4</sup>, T.E.H. Römkens<sup>5</sup>, F. Hoentjen<sup>1</sup> <sup>1</sup>Dept. of Gastroenterology and Hepatology, Radboud Universitair Medisch Centrum, Nijmegen, Nederland, <sup>2</sup>Dept. of Gastroenterology and Hepatology, Franciscus Gasthuis & Vlietland, Rotterdam, Nederland, <sup>3</sup>Dept. of Gastroenterology and Hepatology, Medisch Spectrum Twente, Enschede, Nederland, <sup>4</sup>Dept. of Gastroenterology and Hepatology, Onze Lieve Vrouwe Gasthuis, Amsterdam, Nederland, <sup>5</sup>Dept. of Gastroenterology and Hepatology, Jeroen Bosch Ziekenhuis, 's-Hertogenbosch, Nederland.
- 14.24 Safety and drug survival of methotrexate versus tioguanine after failure of conventional thiopurines in Crohn's disease  
E.H.J. Savelkoul<sup>1</sup>, M.H.J. Maas<sup>1</sup>, M.G.V.M. Russel<sup>2</sup>, T.E.H. Römkens<sup>3</sup>, F. Hoentjen<sup>1</sup> <sup>1</sup>Dept. of Gastroenterology and Hepatology, Radboudumc, Nijmegen, Nederland, <sup>2</sup>Dept. of Gastroenterology and Hepatology, Medisch Spectrum Twente, Enschede, Nederland, <sup>3</sup>Dept. of Gastroenterology and Hepatology, Jeroen Bosch Ziekenhuis, 's Hertogenbosch, Nederland.
- 14.30 Switching within or out of class are the most effective strategies in IBD patients with immunogenicity against anti-TNF antibodies  
S.I. Anjie<sup>1</sup>, J. Hanzel<sup>1</sup>, K.B. Gecse<sup>1</sup>, G.R.A.M. D'Haens<sup>1</sup>, J.F. Brandse<sup>1</sup> <sup>1</sup>Dept. of Gastroenterology and Hepatology, Amsterdam UMC, Amsterdam, Nederland.
- 14.36 Long-term outcomes following a switch from originator Adalimumab to the biosimilar SB5 (IMRALDI) in a real-world IBD cohort  
A.P. Derikx<sup>1</sup>, N. Plevris<sup>2</sup>, L. Lucaciu<sup>2</sup>, H.W. Dolby<sup>2</sup>, C.S. Rees<sup>2</sup>, M. Lyons<sup>2</sup>, S.I. Siakavellas<sup>2</sup>, C. Noble<sup>2</sup>, C. O'hara<sup>2</sup>, L. Merchant<sup>2</sup>, I.D. Arnott<sup>2</sup>, G.R. Jones<sup>2</sup>, C.W. Lees<sup>2</sup> <sup>1</sup>Dept. of Gastroenterology and Hepatology, Radboudumc, Nijmegen, The Netherlands, <sup>2</sup>Dept. of Gastroenterology and Hepatology, Western General Hospital, Edinburgh, Verenigd Koninkrijk.
- 14.42 Gut microbiome and proteomic changes as biomarker of response to vedolizumab in patients with inflammatory bowel disease  
V. Collij<sup>1</sup>, M.A.Y. Klaassen<sup>2</sup>, S. Hu<sup>2</sup>, W.T.C. Uniken Venema<sup>2</sup>, A. Bangma<sup>2</sup>, J.B. Aardema<sup>2</sup>, A.R. Bourgonje<sup>2</sup>, B.H. Jansen<sup>2</sup>, G. Dijkstra<sup>2</sup>, E.A.M. Festen<sup>2</sup>, M.C. Visschedijk<sup>2</sup>, J.N. Samsom<sup>3</sup>, R. Gacesa<sup>2</sup>, A. Vich Vila<sup>2</sup>, R.K. Weersma<sup>2</sup> <sup>1</sup>Dept. of Gastroenterology and Hepatology, University Medical Center Groningen, Groningen, The Netherlands, <sup>2</sup>Dept. of Gastroenterology and Hepatology, Universitair Medisch Centrum Groningen, Groningen, The Netherlands, <sup>3</sup>Dept. of Pediatrics, Erasmus University Medical Center, Rotterdam, The Netherlands.

Donderdag 18 maart 2021

- 14.48 Pregnant women with perianal Crohn's disease: the current guideline on delivery method needs improvement  
*I.J. Schaafsma<sup>1</sup>, F.J. Hoogenboom<sup>2</sup>, G. Dijkstra<sup>1</sup>, J.R. Prins<sup>3</sup>, M.C. Visschedijk<sup>1</sup>* <sup>1</sup>Dept. of Gastroenterology and Hepatology, University of Groningen, University Medical Center Groningen, Groningen, the Net, Groningen, The Netherlands, <sup>2</sup>Dept. of Surgery, University of Groningen, University Medical Center Groningen, Groningen, the Net, Groningen, The Netherlands, <sup>3</sup>Dept. of Gynaecologic Oncology, University of Groningen, University Medical Center Groningen, Groningen, the Net, Groningen, The Netherlands.
- 15.00 Einde van dit programma onderdeel

Voorzitters: A. Inderson en W.B. Nagengast

- 15.30 Optimal timing of rectal diclofenac in preventing post-ERCP pancreatitis  
 C.J. Sperna Weiland<sup>1</sup>, X.J.N.M. Smeets<sup>1</sup>, R.C. Verdonk<sup>2</sup>, A.C. Poen<sup>3</sup>, A. Bhalla<sup>4</sup>, N.G. Venneman<sup>5</sup>, W. Kievit<sup>1</sup>, H.C. Timmerhuis<sup>2</sup>, D.S. Umans<sup>2</sup>, J.E. Van Hooft<sup>6</sup>, M.G. Besselink<sup>7</sup>, H.C. Van Santvoort<sup>8</sup>, P. Fockens<sup>9</sup>, M.J. Bruno<sup>10</sup>, J.P.H. Drenth<sup>1</sup>, E.J.M. Van Geenen<sup>1</sup> <sup>1</sup>Dept. of Gastroenterology and Hepatology, Radboudumc, Nijmegen, Nederland, <sup>2</sup>Dept. of Gastroenterology and Hepatology, St. Antonius ziekenhuis, Nieuwegein, Nederland, <sup>3</sup>Dept. of Gastroenterology and Hepatology, Isala ziekenhuis, Zwolle, Nederland, <sup>4</sup>Dept. of Gastroenterology and Hepatology, Haga ziekenhuis, Den Haag, Nederland, <sup>5</sup>Dept. of Gastroenterology and Hepatology, Medisch Spectrum Twente, Enschede, Nederland, <sup>6</sup>Dept. of Gastroenterology and Hepatology, Leids Universitair Medisch Centrum, Leiden, Nederland, <sup>7</sup>Dept. of Surgery, Amsterdam UMC, Amsterdam, Nederland, <sup>8</sup>Dept. of Surgery, St. Antonius ziekenhuis, Nieuwegein, Nederland, <sup>9</sup>Dept. of Gastroenterology and Hepatology, Amsterdam UMC, Amsterdam, Nederland, <sup>10</sup>Dept. of Gastroenterology and Hepatology, Erasmus MC, Rotterdam, Nederland.
- 15.33 Evaluation of Gastroscopy Referrals in Primary Care in the Netherlands  
 L.M. de Koggel<sup>1</sup>, M.A. Lantinga<sup>1</sup>, F.L. Büchner<sup>2</sup>, M.E. Numans<sup>2</sup>, M. Heringa<sup>3</sup>, J.P.H. Drenth<sup>1</sup>, P.D. Siersema<sup>1</sup>, <sup>1</sup>Dept. of Gastroenterology and Hepatology, Radboudumc, Nijmegen, The Netherlands, <sup>2</sup>Dept. of Public Health, Leids Universitair Medisch Centrum, Leiden, The Netherlands, <sup>3</sup>Dept. of Clinical Pharmacy, SIR Institute for Pharmacy Practice and Policy, Leiden, The Netherlands.
- 15.36 Endoscopic Papillectomy; a Delphi consensus  
 J.A. Fritzsche<sup>1</sup>, P. Fockens<sup>2</sup>, M.J. Bourke<sup>20</sup>, R.P. Voermans<sup>2</sup>, M. Barthet<sup>3</sup>, M.J. Bruno<sup>4</sup>, D.L. Carr-Locke<sup>5</sup>, G. Costamagna<sup>6</sup>, G.A. Coté<sup>7</sup>, P.H. Deprez<sup>8</sup>, M. Giovannini<sup>9</sup>, G.B. Haber<sup>10</sup>, R.H. Hawes<sup>11</sup>, J.J. Hyun<sup>12</sup>, T. Itoi<sup>13</sup>, E. Iwasaki<sup>14</sup>, L. Kylänpäi<sup>15</sup>, H. Neuhaus<sup>16</sup>, J.Y. Park<sup>17</sup>, D.N. Reddy<sup>18</sup>, A. Sakai<sup>19</sup> <sup>1</sup>Dept. of Gastroenterology and Hepatology, Amsterdam University Medical Centers, Amsterdam, Nederland, <sup>2</sup>Dept. of Gastroenterology and Hepatology, Amsterdam UMC, Amsterdam, Nederland, <sup>3</sup>Dept. of Gastroenterology and Hepatology, Assistance Publique des Hôpitaux de Marseille, Marseille, Frankrijk, <sup>4</sup>Dept. of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam, Nederland, <sup>5</sup>Dept. of Gastroenterology and Hepatology, Weill Cornell Medicine, New York Presbyterian Hospital, New York, Verenigde Staten, <sup>6</sup>Dept. of Endoscopy, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Catholic University, Rome, Italië, <sup>7</sup>Dept. of Gastroenterology and Hepatology, Medical University of South Carolina, Charleston, South Carolina, Verenigde Staten, <sup>8</sup>Dept. of Gastroenterology and Hepatology, Cliniques universitaires Saint-Luc, Université Catholique de Louvain, Brussels, België, <sup>9</sup>Dept. of Endoscopy, Paoli-Calmettes Institute, Marseille Cedex, Frankrijk, <sup>10</sup>Dept. of Gastroenterology and Hepatology, NYU Langone Medical Center, New York University, New York, NY, Verenigde Staten, <sup>11</sup>Dept. of Endoscopy, Center for Interventional Endoscopy, AdventHealth, Orlando, Florida, Verenigde Staten, <sup>12</sup>Dept. of Gastroenterology and Hepatology, Korea University Ansan Hospital, Ansan, Zuid-Korea, <sup>13</sup>Dept. of Gastroenterology and Hepatology, Tokyo Medical University, Tokyo, Japan, <sup>14</sup>Dept. of Gastroenterology and Hepatology, Keio University School of Medicine, Tokyo, Japan, <sup>15</sup>Dept. of Gastrointestinal Surgery, Helsinki University Central Hospital, Helsinki, Finland, <sup>16</sup>Dept. of Gastroenterology, Evangelisches Krankenhaus Düsseldorf, Düsseldorf, Duitsland, <sup>17</sup>Dept. of Internal Medicine, Yonsei University College of Medicine, Seoul, Zuid-Korea, <sup>18</sup>Dept. of Gastroenterology, Asian Institute of Gastroenterology Hospitals, Hyderabad, India, <sup>19</sup>Dept. of Gastroenterology, Kobe University Graduate School of Medicine, Kobe, Japan, <sup>20</sup>Dept. of Gastroenterology and Hepatology, Westmead Hospital, Westmead Clinical School, University of Sydney, Sydney, Australië.

- 15.39            Discussie
- 15.48            Endoscopic expert revision of previous histological confirmed flat low-grade dysplasia in Barrett's esophagus  
E.A. de Nieuwenhuis<sup>1</sup>, S.N. van Munster<sup>1</sup>, B.L.A.M. Weusten<sup>2</sup>, L. Alvarez Herrero<sup>2</sup>, A. Bogte<sup>3</sup>, A. Alkhalaf<sup>4</sup>, B.E. Schenk<sup>4</sup>, E. Schoon<sup>5</sup>, W.L. Curvers<sup>5</sup>, A.D. Koch<sup>6</sup>, M.C.W. Spaander<sup>6</sup>, T. Tang<sup>7</sup>, W.B. Nagengast<sup>8</sup>, J. Westerhof<sup>8</sup>, M.H.M.G. Houben<sup>9</sup>, J.J.G.H.M. Bergman<sup>1</sup>, R.E. Pouw<sup>1</sup> <sup>1</sup>Dept. of Gastroenterology and Hepatology, Amsterdam UMC, location VUmc, Amsterdam, The Netherlands, <sup>2</sup>Dept. of Gastroenterology and Hepatology, Sint Antonius Hospital Nieuwegein, Nieuwegein, The Netherlands, <sup>3</sup>Dept. of Gastroenterology and Hepatology, University Medical Center Utrecht, Utrecht, The Netherlands, <sup>4</sup>Dept. of Gastroenterology and Hepatology, Isala Clinics, Zwolle, The Netherlands, <sup>5</sup>Dept. of Gastroenterology and Hepatology, Catharina Hospital, Eindhoven, The Netherlands, <sup>6</sup>Dept. of Gastroenterology and Hepatology, Erasmus Medical Center, Rotterdam, The Netherlands, <sup>7</sup>Dept. of Gastroenterology and Hepatology, IJsselland Hospital, Capelle a/d IJssel, The Netherlands, <sup>8</sup>Dept. of Gastroenterology and Hepatology, University Medical Center Groningen, Groningen, The Netherlands, <sup>9</sup>Dept. of Gastroenterology and Hepatology, Haga Teaching Hospital, Den Haag, The Netherlands.
- 15.51            Poor healing and poor squamous regeneration after radiofrequency ablation therapy for early Barrett's neoplasia: incidence, risk factors, and outcomes  
C.N. Frederiks<sup>1-3</sup>, S.N. van Munster<sup>2-3</sup>, L. Alvarez Herrero<sup>3</sup>, A. Bogte<sup>1</sup>, A. Alkhalaf<sup>4</sup>, B.E. Schenk<sup>4</sup>, E. Schoon<sup>5</sup>, W. Curvers<sup>5</sup>, A. Koch<sup>6</sup>, S.E.M. van de Ven<sup>6</sup>, P.J.F. de Jonge<sup>6</sup>, T. Tang<sup>7</sup>, W.B. Nagengast<sup>8</sup>, F.T.M. Peters<sup>8</sup>, J. Westerhof<sup>8</sup>, M.H.M.G. Houben<sup>9</sup>, J.J. Bergman<sup>2</sup>, R.E. Pouw<sup>2</sup>, B.L.A.M. Weusten<sup>1-3</sup> <sup>1</sup>Dept. of Gastroenterology and Hepatology, University Medical Center Utrecht, Utrecht, Nederland, <sup>2</sup>Dept. of Gastroenterology and Hepatology, Amsterdam University Medical Centers, Amsterdam, Nederland, <sup>3</sup>Dept. of Gastroenterology and Hepatology, St. Antonius Hospital, Nieuwegein, Nederland, <sup>4</sup>Dept. of Gastroenterology and Hepatology, Isala Hospital, Zwolle, Nederland, <sup>5</sup>Dept. of Gastroenterology and Hepatology, Catharina Hospital Eindhoven, Eindhoven, Nederland, <sup>6</sup>Dept. of Gastroenterology and Hepatology, Erasmus Medical Center, Rotterdam, Nederland, <sup>7</sup>Dept. of Gastroenterology and Hepatology, IJsselland Hospital, Cappelle a/d IJssel, Nederland, <sup>8</sup>Dept. of Gastroenterology and Hepatology, University Medical Center Groningen, Groningen, Nederland, <sup>9</sup>Dept. of Gastroenterology and Hepatology, Haga Hospital, Den Haag, Nederland.
- 15.54            Endoscopic submucosal dissection for Barrett's related neoplasia in the Netherlands: results of a nationwide cohort of 130 cases  
EPD Verheij<sup>1</sup>, SN Van Munster<sup>1</sup>, EA Nieuwenhuis<sup>1</sup>, L Van Tilburg<sup>2</sup>, J Offerhaus<sup>3</sup>, SL Meijer<sup>4</sup>, LAA Brosens<sup>3</sup>, BLAM Weusten<sup>5</sup>, A Alkhalaf<sup>6</sup>, BE Schenk<sup>6</sup>, EJ Schoon<sup>7</sup>, WL Curvers<sup>7</sup>, SEM Van de Ven<sup>2</sup>, WB Nagengast<sup>8</sup>, MHMG Houben<sup>9</sup>, JJGHM Bergman<sup>1</sup>, AD Koch<sup>2</sup>, RE Pouw<sup>1</sup> <sup>1</sup>Dept. of Gastroenterology and Hepatology, Amsterdam University Medical Centers, Amsterdam, The Netherlands, <sup>2</sup>Dept. of Gastroenterology and Hepatology, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands, <sup>3</sup>Dept. of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands, <sup>4</sup>Dept. of Pathology, Amsterdam University Medical Centers, Amsterdam, The Netherlands, <sup>5</sup>Dept. of Gastroenterology and Hepatology, University Medical Center Utrecht, Utrecht, The Netherlands, <sup>6</sup>Dept. of Gastroenterology and Hepatology, Isala Clinics, Zwolle, The Netherlands, <sup>7</sup>Dept. of Gastroenterology and Hepatology, Catharina Hospital, Eindhoven, The Netherlands, <sup>8</sup>Dept. of Gastroenterology and Hepatology, University Medical Center Groningen, Groningen, The Netherlands, <sup>9</sup>Dept. of Gastroenterology and Hepatology, Haga Teaching Hospital, Den Haag, The Netherlands.
- 15.57            Disruption or disconnection of the pancreatic duct in patients with severe acute pancreatitis: a large prospective multi-center cohort  
HC Timmerhuis<sup>1</sup>, SM van Dijk<sup>2</sup>, RA Hollemans<sup>3</sup>, CJ Sperna Weiland<sup>4</sup>, L Boxhoorn<sup>5</sup>, BJ Witteman<sup>6</sup>, R Quispel<sup>7</sup>, MP Schwartz<sup>8</sup>, J-W Poley<sup>9</sup>, MJ Bruno<sup>9</sup>, JE van Hooft<sup>10</sup>, RP Voermans<sup>11</sup>, MG Besselink<sup>12</sup>, TL Bollen<sup>13</sup>, RC Verdonk<sup>14</sup>, HC van Santvoort<sup>15</sup> <sup>1</sup>Dept. of

Surgery, St Antoniusziekenhuis, Nieuwegein, Nederland, <sup>2</sup>Dept. of Surgery, AmsterdamUMC, locatie AMC, Amsterdam, Nederland, <sup>3</sup>Dept. of Surgery, St. Antoniusziekenhuis, Nieuwegein, Nederland, <sup>4</sup>Dept. of Gastroenterology, Radboudumc, Nijmegen, Nederland, <sup>5</sup>Dept. of Gastroenterology, AmsterdamUMC, locatie AMC, Amsterdam, Nederland, <sup>6</sup>Dept. of Gastroenterology and Hepatology, Ziekenhuis Gelderse Vallei, Ede, Nederland, <sup>7</sup>Dept. of Gastroenterology and Hepatology, Reinier de Graaf Gasthuis, Delft, Nederland, <sup>8</sup>Dept. of Gastroenterology and Hepatology, MeanderMC, Amersfoort, Nederland, <sup>9</sup>Dept. of Gastroenterology and Hepatology, ErasmusMC, Rotterdam, Nederland, <sup>10</sup>Dept. of Gastroenterology and Hepatology, LUMC, Leiden, Nederland, <sup>11</sup>Dept. of Gastroenterology and Hepatology, AmsterdamUMC, locatie AMC, Amsterdam, Nederland, <sup>12</sup>Dept. of Gastrointestinal Surgery, AmsterdamUMC, locatie AMC, Amsterdam, Nederland, <sup>13</sup>Dept. of Radiology, St. Antoniusziekenhuis, Nieuwegein, Nederland, <sup>14</sup>Dept. of Gastroenterology and Hepatology, St. Antoniusziekenhuis, Nieuwegein, Nederland, <sup>15</sup>Dept. of Gastrointestinal Surgery, St. Antoniusziekenhuis, Nieuwegein, Nederland.

16.00

Lumen-apposing metal stents versus double-pigtail plastic stents in the endoscopic step-up approach for infected necrotizing pancreatitis

L Boxhoorn<sup>1</sup>, RC Verdonk<sup>2</sup>, MGH Besselink<sup>3</sup>, MA Boermeester<sup>3</sup>, TL Bollen<sup>4</sup>, SA Bouwense<sup>5</sup>, VC Cappendijk<sup>6</sup>, WL Curvers<sup>7</sup>, CH Dejong<sup>5</sup>, SM van Dijk<sup>3</sup>, HM van Dullemen<sup>8</sup>, CHJ van Eijck<sup>9</sup>, EJM van Geenen<sup>10</sup>, M Hadithi<sup>11</sup>, WL Hazen<sup>12</sup>, P Honkoop<sup>13</sup>, JE Van Hooft<sup>14</sup>, MAJM Jacobs<sup>1</sup>, E Kouw<sup>15</sup>, SD Kuiken<sup>16</sup>, M Ledebroer<sup>17</sup>, VB Nieuwenhuijs<sup>18</sup>, LE Perk<sup>19</sup>, JW Poley<sup>20</sup>, R Quispel<sup>21</sup>, R de Ridder<sup>22</sup>, HC van Santvoort<sup>23</sup>, MWJ Stommel<sup>24</sup>, HC Timmerhuis<sup>25</sup>, BJ Witteman<sup>26</sup>, DS Umans<sup>1</sup>, NG Venneman<sup>27</sup>, FP Vleggaar<sup>28</sup>, RL van Wanrooij<sup>1</sup>, CJ Sperna Weiland<sup>10</sup>, MJ Bruno<sup>20</sup>, P Fockens<sup>1</sup>, RP Voermans<sup>1</sup> <sup>1</sup>Dept. of Gastroenterology and Hepatology, Amsterdam UMC, Amsterdam, The Netherlands, <sup>2</sup>Dept. of Gastroenterology and Hepatology, St. Antonius Hospital, Nieuwegein, The Netherlands, <sup>3</sup>Dept. of Surgery, Amsterdam UMC, Amsterdam, The Netherlands, <sup>4</sup>Dept. of Radiology, St. Antonius Hospital, Nieuwegein, The Netherlands, <sup>5</sup>Dept. of Surgery, Maastricht UMC+, Maastricht, The Netherlands, <sup>6</sup>Dept. of Radiology, Jeroen Bosch Hospital, Den Bosch, The Netherlands, <sup>7</sup>Dept. of Gastroenterology and Hepatology, Catharina Hospital, Eindhoven, The Netherlands, <sup>8</sup>Dept. of Gastroenterology and Hepatology, University Medical Center Groningen, Groningen, The Netherlands, <sup>9</sup>Dept. of Surgery, Erasmus MC University Medical Center, Rotterdam, The Netherlands, <sup>10</sup>Dept. of Gastroenterology and Hepatology, Radboudumc, Nijmegen, The Netherlands, <sup>11</sup>Dept. of Gastroenterology and Hepatology, Maasstad Hospital, Rotterdam, The Netherlands, <sup>12</sup>Dept. of Gastroenterology and Hepatology, Elisabeth-TweeSteden Hospital, Tilburg, The Netherlands, <sup>13</sup>Dept. of Gastroenterology and Hepatology, Albert Schweitzer Hospital, Dordrecht, The Netherlands, <sup>14</sup>Dept. of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, The Netherlands, <sup>15</sup>Dept. of Gastroenterology and Hepatology, Gelre Hospital, Apeldoorn, The Netherlands, <sup>16</sup>Dept. of Gastroenterology and Hepatology, OLVG, Amsterdam, The Netherlands, <sup>17</sup>Dept. of Gastroenterology and Hepatology, Deventer Hospital, Deventer, The Netherlands, <sup>18</sup>Dept. of Surgery, Isala Clinics, Zwolle, The Netherlands, <sup>19</sup>Dept. of Gastroenterology and Hepatology, Haaglanden Medical Center, The Hague, The Netherlands, <sup>20</sup>Dept. of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam, The Netherlands, <sup>21</sup>Dept. of Gastroenterology and Hepatology, Reinier de Graaf Gasthuis, Delft, The Netherlands, <sup>22</sup>Dept. of Gastroenterology and Hepatology, Maastricht UMC+, Maastricht, The Netherlands, <sup>23</sup>Dept. of Surgery, University Medical Center Utrecht, Utrecht, The Netherlands, <sup>24</sup>Dept. of Surgery, Radboudumc, Nijmegen, The Netherlands, <sup>25</sup>Dept. of Surgery, St. Antonius Hospital, Nieuwegein, The Netherlands, <sup>26</sup>Dept. of Gastroenterology and Hepatology, Hospital Gelderse Vallei, Ede, The Netherlands, <sup>27</sup>Dept. of Gastroenterology and Hepatology, Medisch Spectrum Twente, Enschede, The Netherlands, <sup>28</sup>Dept. of Gastroenterology and Hepatology, University Medical Center Utrecht, Utrecht, The Netherlands.

- 16.03      Postponed or immediate drainage of infected necrotizing pancreatitis (POINTER): a multicenter randomized trial  
L. Boxhoorn<sup>1</sup>, S.M. van Dijk<sup>2</sup>, J. van Grinsven<sup>2</sup>, R.C. Verdonk<sup>3</sup>, M.A. Boermeester<sup>2</sup>, TL Bollen<sup>4</sup>, SA Bouwense<sup>5</sup>, MJ Bruno<sup>6</sup>, VC Cappendijk<sup>7</sup>, CH Dejong<sup>5</sup>, P van Duijvendijk<sup>8</sup>, CHJ van Eijck<sup>9</sup>, P Fockens<sup>1</sup>, H van Goor<sup>10</sup>, M Hadithi<sup>11</sup>, NDH Hallensleben<sup>12</sup>, JW Haveman<sup>13</sup>, MAJM Jacobs<sup>1</sup>, JM Jansen<sup>14</sup>, MPM Kop<sup>15</sup>, KP van Lienden<sup>4</sup>, ER Manusama<sup>16</sup>, JSD Mieog<sup>17</sup>, I.Q. Molenaar<sup>18</sup>, VB Nieuwenhuijs<sup>19</sup>, AC Poen<sup>20</sup>, JW Poley<sup>6</sup>, M van de Poll<sup>5</sup>, R Quispel<sup>21</sup>, TEH Römken<sup>22</sup>, MP Schwartz<sup>23</sup>, TC Seerden<sup>24</sup>, MWJ Stommel<sup>10</sup>, JWA Straathof<sup>25</sup>, HC Timmerhuis<sup>26</sup>, NG Venneman<sup>27</sup>, W van de Vrie<sup>28</sup>, BJ Witteman<sup>29</sup>, MGW Dijkgraaf<sup>30</sup>, HC van Santvoort<sup>18</sup>, MGH Besselink<sup>2</sup> <sup>1</sup>Dept. of Gastroenterology and Hepatology, Amsterdam UMC, Amsterdam, The Netherlands, <sup>2</sup>Dept. of Surgery, Amsterdam UMC, Amsterdam, The Netherlands, <sup>3</sup>Dept. of Gastroenterology and Hepatology, St. Antonius Hospital, Nieuwegein, The Netherlands, <sup>4</sup>Dept. of Radiology, St. Antonius Hospital, Nieuwegein, The Netherlands, <sup>5</sup>Dept. of Surgery, Maastricht UMC+, Maastricht, The Netherlands, <sup>6</sup>Dept. of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam, The Netherlands, <sup>7</sup>Dept. of Radiology, Jeroen Bosch Hospital, Den Bosch, The Netherlands, <sup>8</sup>Dept. of Surgery, Gelre Hospitals, Apeldoorn, The Netherlands, <sup>9</sup>Dept. of Surgery, Erasmus MC University Medical Center, Rotterdam, The Netherlands, <sup>10</sup>Dept. of Surgery, Radboudumc, Nijmegen, The Netherlands, <sup>11</sup>Dept. of Gastroenterology and Hepatology, Maasstad Hospital, Rotterdam, The Netherlands, <sup>12</sup>Dept. of Anesthesiology, Erasmus MC University Medical Center, Rotterdam, The Netherlands, <sup>13</sup>Dept. of Surgery, University Medical Center Groningen, Groningen, The Netherlands, <sup>14</sup>Dept. of Gastroenterology and Hepatology, OLVG, Amsterdam, The Netherlands, <sup>15</sup>Dept. of Radiology, Amsterdam UMC, Amsterdam, The Netherlands, <sup>16</sup>Dept. of Surgery, Medical Center Leeuwarden, Leeuwarden, The Netherlands, <sup>17</sup>Dept. of Surgery, Leiden University Medical Center, Leiden, The Netherlands, <sup>18</sup>Dept. of Surgery, University Medical Center Utrecht, Utrecht, The Netherlands, <sup>19</sup>Dept. of Surgery, Isala Clinics, Zwolle, The Netherlands, <sup>20</sup>Dept. of Gastroenterology and Hepatology, Isala Clinics, Zwolle, The Netherlands, <sup>21</sup>Dept. of Gastroenterology and Hepatology, Reinier de Graaf Gasthuis, Delft, The Netherlands, <sup>22</sup>Dept. of Gastroenterology and Hepatology, Jeroen Bosch Hospital, Den Bosch, The Netherlands, <sup>23</sup>Dept. of Gastroenterology and Hepatology, Meander Medical Center, Amersfoort, The Netherlands, <sup>24</sup>Dept. of Gastroenterology and Hepatology, Amphia Hospital, Breda, The Netherlands, <sup>25</sup>Dept. of Gastroenterology and Hepatology, Maxima Medical Center, Veldhoven, The Netherlands, <sup>26</sup>Dept. of Surgery, St. Antonius Hospital, Nieuwegein, The Netherlands, <sup>27</sup>Dept. of Gastroenterology and Hepatology, Medisch Spectrum Twente, Enschede, The Netherlands, <sup>28</sup>Dept. of Gastroenterology and Hepatology, Albert Schweitzer Hospital, Dordrecht, The Netherlands, <sup>29</sup>Dept. of Gastroenterology and Hepatology, Hospital Gelderse Vallei, Ede, The Netherlands, <sup>30</sup>Dept. of Epidemiology and Biostatistics, Amsterdam UMC, Amsterdam, The Netherlands.
- 16.06      Discussie
- 16.30      Einde van dit programma onderdeel

---

**Symposium – V&VN MDL – Endoscopie**

---

**Studio 3**

Voorzitters: *A.P.M. Boersen*

- 11.30 Anticoagulantia medicatie tijdens endoscopische ingrepen: een bloedstollende ingreep?  
*Dr. P.R. van der Valk, Internist-hematoloog, Van Creveldkliniek, Utrecht*
- 11.50 Classificatie van poliepen  
*Dr. F.H.J. Wolfhagen, MDL-arts, Albert Schweitzer Ziekenhuis, Dordrecht*
- 12.10 Endo-Echografie  
*Dr. L.M. Kager, MDL-arts, Noordwest Ziekenhuisgroep Alkmaar*
- 12.30 Einde van dit programma onderdeel

---

**Symposium – V&VN MDL – IBD**

---

**Studio 3**

Voorzitters: *M.H. François-Verwey*

- 14.00 Microscopische colitis  
*Dr. H.H. Fidder, MDL-arts, Universitair Medisch Centrum Utrecht*
- 14.20 Leefstijladviezen en IBD  
*R. Theeuwen, verpleegkundig specialist IBD, Leids Universitair Medisch Centrum*
- 14.40 PSC en CU  
*Dr. A.C. de Vries, MDL-arts, Erasmus MC, Rotterdam*
- 15.00 Einde van dit programma onderdeel

---

**Abstractsessie – V&VN MDL**

---

**Studio 2**

Voorzitters: *C.J.R. Verstraete en A.N. Reijm*

- 17.00 Factors influencing health related quality of life in patients with Barrett's Esophagus  
*M. van der Ende-van Loon, verpleegkundig specialist/ PhD kandidaat, Catharina Ziekenhuis, Eindhoven*
- 17.15 De IBD-verpleegkundige als nieuwe functie in het UMC Utrecht  
*B. Muskens, verpleegkundig specialist i.o, Universitair Medisch Centrum Utrecht*
- 17.30 Kwaliteitsverbeterplan over voorlichting bij oncologische patiënten, die in verband met passageklachten een stent geplaatst krijgen, in de hoge tractus digestivus.  
*W. Theunisse, MDL & Oncologieverpleegkundige, Albert Schweitzer Ziekenhuis, Dordrecht*
- 17.45 Fecale incontinentie (FI) bij de oudere IBD patient  
*D. van den Berg, verpleegkundig specialist IBD, Leids Universitair Medisch Centrum*
- 18.00 Afsluiting programma onderdeel